Edith Cowan University

Research Online
Theses: Doctorates and Masters

Theses

2018

Genetic determinants of rates of cognitive decline in preclinical
Alzheimer’s Disease
Tenielle L. S. Porter
Edith Cowan University

Follow this and additional works at: https://ro.ecu.edu.au/theses
Part of the Medicine and Health Sciences Commons

Recommended Citation
Porter, T. L. (2018). Genetic determinants of rates of cognitive decline in preclinical Alzheimer’s Disease.
https://ro.ecu.edu.au/theses/2114

This Thesis is posted at Research Online.
https://ro.ecu.edu.au/theses/2114

Edith Cowan University
Copyright Warning
You may print or download ONE copy of this document for the purpose
of your own research or study.
The University does not authorize you to copy, communicate or
otherwise make available electronically to any other person any
copyright material contained on this site.
You are reminded of the following:
 Copyright owners are entitled to take legal action against persons
who infringe their copyright.
 A reproduction of material that is protected by copyright may be a
copyright infringement. Where the reproduction of such material is
done without attribution of authorship, with false attribution of
authorship or the authorship is treated in a derogatory manner,
this may be a breach of the author’s moral rights contained in Part
IX of the Copyright Act 1968 (Cth).
 Courts have the power to impose a wide range of civil and criminal
sanctions for infringement of copyright, infringement of moral
rights and other offences under the Copyright Act 1968 (Cth).
Higher penalties may apply, and higher damages may be awarded,
for offences and infringements involving the conversion of material
into digital or electronic form.

Genetic determinants of rates of cognitive decline in
preclinical Alzheimer’s Disease

This thesis is presented for the degree of
Doctor of Philosophy

Tenielle Louise Sandra Porter

Edith Cowan University
School of Medical and Health Sciences
2018

Genetic determinants of rates of cognitive decline in
preclinical Alzheimer’s Disease

Tenielle Louise Sandra Porter

Doctoral Thesis

April 2018

School of Medical and Health Sciences
EDITH COWAN UNIVERSITY

Principal Supervisor:
Associate Professor Simon Matthew Laws
Co-Principal Supervisor:
Associate Professor Giuseppe Verdile
Associate Supervisors:
Dr Samantha Burnham

Associate Professor David Groth

This page intentionally left blank

i

USE OF THESIS

The Use of Thesis statement is not included in this version of the thesis.

This page intentionally left blank

iii

Declaration

I certify that this thesis does not, to the best of my knowledge and belief:

(i) Incorporate with acknowledgement any material previously submitted for a degree
or diploma in any institution of higher education;

(ii) Contain any material previously published or written by another person except
where due reference is made in the text; or

(iii) Contain any defamatory material

I also grant permission for the Library at Edith Cowan University to make duplicate
copies of my thesis as required

Tenielle Louise Sandra Porter

_

Date: 30/04/2018

iv

This page intentionally left blank

v

Abstract

Background
In 2015 the number of people worldwide living with Dementia was 46.8 million, with
approximately 50-75% of these cases being clinically defined as Alzheimer’s disease
(AD). Despite extensive efforts, clinical trials have so far failed to yield a treatment that
successfully addresses the underlying cause of AD. This lack of treatment has been
suggested, in part, to be a result of late stage of intervention in current clinical trial
design. For this reason, greater focus has been placed on preclinical trials and in turn
both the identification of individuals at-risk for AD and, amongst these, those that are
expected to decline over the course of a trial. While brain imaging to determine Aβamyloid burden has utility in identifying individuals with preclinical AD, further work
needs to be conducted to determine what influences rates of change during these early
disease stages. Of particular focus is the rate of decline in cognitive performance, as it
is the primary outcome measure of efficacy in clinical trials. A number of genetic
variants have been associated with cognitive performance, however additional research
needs to be conducted to accurately understand the influence that genetic variation has
on cognition in preclinical AD.

Aims
Initially the aim of this thesis was to assess the combined genetic influence of
established AD risk genetic variants on preclinical cognitive performance, specifically
using AD-risk effect-size weighted polygenic risk scores (PRSs) (Chapter 2). It was
then aimed to evaluate the effects on cognitive rates of change in preclinical AD of
genes with a priori evidence for association with cognition, both individually (Chapter
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3) and then when combined (Chapter 4). The results of the preceding chapters informed
the final aim which was to determine a novel method of weighting individual variants
in genes associated with AD-risk and/or cognition, for use in a genetic risk score that
would improve the prediction of preclinical cognitive rates of change (Chapter 5).

Methods
All studies presented in this thesis utilised data from the highly characterised Australian
Imaging, Biomarkers and Lifestyle Study of Aging (AIBL). The AIBL study is a
longitudinal cohort study collecting data at 18-monthly intervals, currently consisting
of 7.5 years of follow up. Individuals investigated in this thesis had been Positron
Emission Tomography (PET) imaged to determine neocortical amyloid burden.
Further, all individuals were classified as Αβhigh or Αβlow based on tracer specific cut
offs. In addition, a subset of these samples underwent lumbar puncture for CSF
collection at the study baseline, and Aβ42, total-tau and phospho-tau were quantified.
Finally, based on the AIBL neuropsychological test battery, three cognitive composites
previously developed were calculated for all participants. The cognitive composites
investigated were; verbal episodic memory, a statistically driven global cognition
composite, and the Pre-Alzheimer’s Cognitive Composite.

The AD-risk weighted PRS (Chapter 2) consisted of 22 genetic variants associated with
AD classification, and was calculated by weighting individual variants based on their
previously published associations with risk for AD. A statistically derived Cognitive
Genetic Risk Profile (Cog-GRP), specifically driven by verbal episodic memory, was
developed using a decision tree analysis (Chapter 4). Finally, a 27 genetic variant
cognition weighted PRS (cwPRS), was developed and tested in a preclinical AD sample
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(Chapter 5). For the cwPRS, effect sizes for decline in a verbal episodic memory were
determined individually for all variants in a reference sample. The resulting effect sizes
were then used to calculate the cwPRS for each participant in a test sample (Chapter 5).
For both the AD-risk weighted PRS (Chapter 2) and the cwPRS (Chapter 5), PRS
calculations were conducted with both the inclusion and exclusion of the major genetic
risk factor for, Apolipoprotein E (APOE).

In all studies, linear mixed models were used to investigate associations between
genetic factors, independent or in combination, and longitudinal rates of cognitive
performance.

Results
In CN older adults the AD-risk weighted PRS, both including and excluding APOE,
was positively correlated with brain and blood biomarkers, specifically; brain Aβ
burden, CSF total-tau and phospho-tau (Chapter 2). When investigating cognitive
performance, specifically in CN Αβhigh participants, significant associations with
baseline and longitudinal cognition were only observed in the AD-risk weighted PRS
with APOE (Chapter 2).

When investigating gene variants previously reported to influence cognition, in CN
Αβhigh participants, no independent associations were observed for any variant (Chapter
3). However, in the same sample, after interaction with APOE e4, significant
associations were observed for variants in the Kidney Brain Expressed Protein (KIBRA)
and Spondin-1 (SPON1) genes (Chapter 3). The combination of variants investigated
in Chapter 3, with additional variants, resulted in the development of the Cog-GRP
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(Chapter 4). The Cog-GRP was able to delineate four groups: APOE ε4+ Risk, APOE
ε4+ Resilient, APOE ε4- Risk, APOE ε4- Resilient, with the ε4+ Risk group reporting
significantly faster decline in cognition than all other groups (Chapter 4).

Finally, a PRS encompassing a combination of AD-risk genes (Chapter 2) and
cognitive-risk genes (Chapters 3 and 4), weighted by episodic memory (cwPRS), was
reported to be associated with preclinical longitudinal cognitive performance (Chapter
5). Further, these associations were observed irrespective of the presence or absence of
APOE in the calculation of the cwPRS (Chapter 5).

Conclusions
The work presented in this thesis provides an in depth investigation of genetic
influences in preclinical AD, particularly on cognitive performance. Importantly, it
supports the hypothesis that there is are differences between the genetic architectures
of AD-risk and AD progression. The results presented here support the use of
combinatory approaches when investigating genetic influence. Finally, reported here is
a novel method for PRS weighting, with the ability to predict preclinical cognitive
performance in the presence and absence of APOE. Further investigation is required in
cohorts with comparable data to the AIBL study, to validate the methods explored in
this thesis, allowing for their eventual use in a clinical setting.
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Chapter 1
Please note that this online copy of the thesis does not contain the complete version
of Chapter 1

CHAPTER 1: General Introduction

1.1 Dementia and Alzheimer’s Disease

In 2015 there were almost 900 million people over the age of 60 [1]. As the global
population continues to age there is a growing focus on age-associated diseases such as
Dementia. Dementia is described generally as progressive decline in a patient’s
cognitive functioning greater than what is expected to occur in normal aging. The term
“Dementia” does not define a single disease, but describes several diseases typified by
the detrimental changes in brain function. Domains in which these changes occur
include language, memory, perception, personality and cognitive skills [2].

In 2015 46.8 million people globally were living with dementia, with this number
expected to double every 20 years [1]. It was estimated that there are 9.9 million new
cases a year, or one new case every 3.2 seconds [1]. In Australia alone there are
approximately 410,000 people with Dementia [3]. Further, in 2015 dementia was the
second leading cause of death in Australia [4].

In addition to the human cost of dementia there is a significant economic cost. The
global cost of dementia increased by USD$214 billion dollars between 2010 and 2015,
rising from USD$604 to USD$818 billion [1]. These costs include social care,
professional and volunteer, and medical care [1]. It has been estimated that dementia
will cost USD$1 trillion by 2018 [1]. It has been predicted that by delaying the onset
of dementia by 5 years, the number of people with the condition in Australia could be
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reduced by around one third [5]. Additionally, in America, a study was conducted that
reported delaying the onset of Alzheimer’s disease (AD) by 5 years would result in an
economic saving of USD$935 billion over 10 years [6].

It has been reported that 50-75% of dementia cases are clinically defined as
Alzheimer’s Disease (AD) [2, 7]. AD is characterised by neuronal loss, abnormal
protein deposition in the brain, and the deterioration of both cognitive function and the
ability to perform activities of daily living.

1.1.1 Pathological Features
The pathological features of AD can be divided into macroscopic structural changes to
the brain, and the presence in increased concentrations of extra- and intracellular
fibrous protein deposits. Importantly, it is generally increased concentrations of these
proteins, due to inefficient clearance or over production, which results in pathogenicity
[8]. It has previously been observed that low concentrations have a non-pathogenic
effect in cognitively normal older adults (CN) [9].

1.1.1.1 Cerebral Atrophy
The major macroscopic hallmark of AD is the progressive loss of brain volume, termed
cerebral atrophy (Figure 1.1.1). The brain regions most significantly affected by
atrophy have been reported to change as the disease develops [10, 11]. It has been
observed that hippocampal atrophy occurs earliest in the disease process, followed by
atrophy of the temporal parietal lobes, and in the late disease stages the frontal lobe
[10]. Significant atrophy of the medial parietal lobe has been observed throughout the
disease [10, 12]. A number of studies have reported hippocampal volume significantly
2

reduced in Mild Cognitive Impairment (MCI) [13] and AD [13] when compared to
cognitively normal (CN) individuals. Additionally, longitudinal rates of hippocampal
atrophy have been associated with progression to AD (from MCI) [14], and
classification of AD [15].

Figure 1.1.1. Cerebral Atrophy
Representation of the brain of a cognitively normal older adult when compared to that
of an Alzheimer’s patient, displaying the gross structural changes associated with the
disease. Image sourced from the BrightFocus Foundation (2000).
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1.1.1.2 Cerebral Amyloid Angiopathy
The accumulation of Amyloid Beta (Ab-amyloid; hereby abbreviated to Ab) in the
cerebral and meningeal blood vessels, Cerebral Amyloid Angiopathy (CAA), is a
prominent hallmark in AD (Figure 1.1.2, [16]). The most common, and most severely
affected, brain region affected by CAA is the occipital lobe, followed by the parietal,
frontal and temporal [17-19]. Sporadic age-related CAA has been observed in the brains
of healthy elderly individuals [20, 21], however it is more prevalent in those of AD
patients [21, 22]. Further, CAA has been reported occurring more frequently in
pathology confirmed AD than in other diseases leading to dementia [18, 21].

1.1.1.3 Senile Amyloid Plaques
Senile amyloid plaques, or neuritic plaques, are the most commonly associated
pathological hallmark of AD (Figure 1.1.3). Senile amyloid plaques have been used in
the post-mortem diagnosis of AD, due to their occurrence being uncommon in other
neurodegenerative disorders. The initial deposition of amyloid plaques occurs through
the frontal, parietal, temporal, or occipital neocortex [24]. These areas are followed by
the entorhinal region and addition subcortical regions, and eventually the cerebellum
and brainstem [24]. A number of protein components make up amyloid plaques
including; a core of insoluble Aβ [25, 26], surrounded by apolipoprotein E (ApoE), α2macroglobulin, interleukins, α2-macroglobulin receptor, and low-density lipoprotein
receptor-related protein [27-30].
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Figure 1.1.2. Cerebral Amyloid Angiopathy
(A) Mild, (B) moderate, and (C) severe cerebral amyloid angiopathy (CAA) in the
meningeal vessels of the temporal lobe, immunohistochemistry with anti-amyloid
antibody 4G8, scale bar: 50 µm. Image sourced from [23].

Figure 1.1.3. Senile Amyloid Plaques
Advanced stage AD patient’s temporal cortex with senile amyloid plaques evident
(brown), immunochemistry with anti-amyloid antibody 4G8, 100× magnification.
Image sourced from [31].
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1.1.1.3.1 Amyloid Beta
Aβ, the major component of senile amyloid plaques, is a small 4-5kDa protein found
in the brain, CSF and blood of CN older adults and AD patients [26]. Proteolytic
cleavage of the amyloid precursor protein (APP), a 110-135kDa transmembrane
glycoprotein, results in the generation of Aβ and other peptides. The cleavage of APP
to produce Aβ is via the amyloidogenic pathway (Figure 1.1.4A, E-G), which occurs in
healthy CN individuals but is favoured in AD. APP is first cleaved at the N-terminus
of the Aβ domain by β-site APP cleaving enzyme (BACE-1) (Figure 1.1.4E), producing
soluble APPβ and the C-terminal of APP (C99; Figure 1.1.4F). C99 is then cleaved
within the transmembrane domain by γ-secretase, releasing Aβ and the APP
intracellular domain (AICD; Figure 1.1.4F, G). Cleavage of APP via the nonamyloidogenic pathway involves cleavage within the Aβ domain by α-secretase,
precluding Aβ production (Figure 1.1.4A-D). Due to differences in cleavage sites
several Aβ isoforms are produced including; Aβ1-42, Aβ4-42, Aβ1-40 and pGluAβ3-42. It
has been shown that in the AD brain, there are higher concentrations of Aβ1-42, the more
toxic Aβ isoform. This toxicity is due to its increased ability to aggregate, which results
from two additional hydrophobic amino acids at the C terminus of the peptide.

Aβ accumulation occurs by the aggregation of monomeric Aβ into soluble aggregates
(dimers, trimers and tetramers), collectively termed oligomers. Evidence suggests these
soluble oligomers are the toxic species associated with AD [32-35]. Oligomers further
aggregate into protofibrils and fibrils, with the aggregation of fibrils leading to the
senile plaque formation. Proposed mechanisms of oligomer toxicity include;
mitochondrial dysfunction [36, 37], synaptic toxicity [38], membrane depolarisation
[39], oxidative stress [40], and inhibition of long-term potentiation [41, 42].
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Figure 1.1.4. APP Processing
Non-amyloidogenic (A, B, C, D) and amyloidogenic (A, E, F, G) Amyloid Precursor
Protein (APP) processing. In the non-amyloidogenic pathway, APP (A) is cleaved by
a-secretase within the Ab domain (B), releasing a-APPs and C83 (C). C83 is then
cleaved by g-secretase within the transmembrane or lipid membrane (C), releasing p3
and the APP intracellular domain (AICD; D). The amyloidogenic pathway involves
APP (A) being cleaved by β-site APP Cleaving Enzyme (BACE-1) within at the Nterminus of the Ab domain (E), releasing a-APPs and C99 (F). C99 is then cleaved by
g-secretase within the lipid membrane (F), releasing Ab and AICD (G).
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1.1.1.4 Neurofibrillary Tangles
Neurofibrillary tangles (NFT) are described as bundles of paired, helically wound
filaments present in the cytoplasm of neurons (Figure 1.1.5, [43]). It has been observed
that the density of NFTs is correlated with the severity of AD [44]. NFTs have been
shown to be concentrated in the entorhinal cortex, hippocampus, amygdala, and frontal,
temporal, and parietal lobes [45]. The main component of NFTs is aggregated
hyperphosphorylated insoluble microtubule-associated protein tau (MAPT, Tau) [4648].

1.1.1.4.1 Tau
Tau, encoded by the MAPT gene located on chromosome 17, is expressed in 6 isoforms
ranging from 45-65kDa, which are produced by the alternative splicing of the mRNA.
The main function of the tau protein is the stabilisation of microtubules which constitute
the neuronal cytoskeleton [50]. Phosphorylation of tau occurs normally as a method of
microtubule binding regulation [51]. However, hyperphosphorylation is proposed to
be, in some cases, a result of up-regulation of kinases that interact with proteins
involved in APP processing [52]. The hyperphosphorylated tau is hypothesised to alter
the binding of microtubules and result in aggregation [51]. This aggregation leads to
the reduction in tau’s ability to stabilise dendrite and axon branches, leading to synaptic
loss.
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Figure 1.1.5. Neurofibrillary Tangles
Sections of an Alzheimer’s disease patient’s hippocampus, immunochemistry with
anti-tau antibody. (A) A number of neurofibrillary tangles (NFT) are observed with
examples highlighted by red arrows (180× magnification). (B) Two NFTs present (red
arrows), as well as two neurons with low levels of tau immunoreactivity in the ‘pretangle’ stage (black arrows; 360× magnification). Image sourced from [49].
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1.1.2 Clinical Features
The deterioration of memory, cognition and the ability to perform functions required
for daily living characterises the clinical presentation of AD [53]. Initially, patients find
difficulty in learning and retaining new information with little impact on older
memories. A patient in the early disease stages will also begin to struggle when
organising complex tasks of daily living [53]. Further, neuropsychological tests will be
able to observe in some patients subtle decline in vocabulary and speech fluency [54].
Finally, patients can experience some disorientation and issues with navigation during
the early disease stages [55].

This progresses gradually to the loss of recent memories, obvious difficulties when
verbally expressing themselves, and the inability to perform functions of daily life
without supervision [53]. Additionally, disease progression is accompanied by the
deterioration of facets of visual processing including; disorientation, impaired
recognition of known faces and delusions [56].

Most cognitive functions are impacted in severely demented AD patients. In particular,
loss of early memories and the ability to verbally communicate characterise this stage
[54]. Additionally, misunderstandings of carer’s actions can lead to aggressive
behaviour by patients [57, 58]. During the late disease stage, impairment of daily living
tasks becomes so severe it results in a significant reduction in life expectancy [59].
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1.1.3 Diagnosis and Monitoring
Definitive AD diagnosis requires post-mortem identification of neuropathological
hallmarks in the brain of the patient [60]. However, clinical assessment, cerebrospinal
fluid (CSF) and blood biomarkers, and brain imaging can provide tentative diagnoses.
Further, these techniques, in particular brain imaging, have the ability to monitor
disease progression from preclinical to symptomatic AD.

1.1.3.1 Neuropsychological Testing
In recent years there have been revisions of the criteria previously used in the diagnosis
of AD to reflect the increased understanding of the disease. The National Institute of
Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease
and Related Disorders Association (NINCDS-ADRDA) criteria published in 1984,
initially characterised a patient’s likelihood of having AD (definite, probable, possible,
unlikely) based on the number of cognitive domains (memory, language, perceptual
skills, attention, constructive abilities, orientation, problem solving, functional abilities)
impaired [61]. The National Institute on Aging/Alzheimer’s Association (NIA/AA)
updated guidelines included the addition of measurements of changes occurring in the
brain as measured by biomarkers [62].

The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) 2013
update included the renaming of Dementia to ‘major neurocognitive disorder’ (NCD)
and the recognition of early cognitive decline (mild NCD) [63]. The DSM-5 diagnoses
NCD by the observing cognitive impairment as the defining feature of a patient’s
impairment. Further, the cognitive symptoms observed must impair the patient’s ability
to function in daily life [63]. The cognitive domains affected as presented in the DSM-
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5 include; complex attention, executive function, learning and memory, language,
perceptual-motor function and social cognition. Mild NCD is diagnosed by the modest
impairment of the previously mentioned cognitive domains from previous
performance, while not interfering with independence in daily activity. The diagnosis
of NCD or mild NCD is followed by the identification of the causative disorder (e.g.
AD) based on the domains affected and the order in which they are affected [63].

There are a number of neuropsychological assessments used to evaluate cognitive
function for the diagnostic criteria above. These assessments have also been used to
monitor disease progression and symptoms in patients and decline in at risk or healthy
individuals. Table 1.1.1 lists the commonly utilised cognitive assessments in AD as
well as the cognitive domains they aim to measure. The combination of results from
these assessments into domain specific composite scores has been shown to improve
the measurement of subtle preclinical cognitive decline [64-67].

1.1.3.2 Neuroimaging
Neuropsychological testing alone is not accurate in diagnosing early stages of AD,
where clinical features are not pronounced. For this reason, much research focus has
been on the observation of biological changes occurring as the disease progresses. The
ability to monitor pathological changes early is favourable due to the extensive
preclinical stage in AD. Brain imaging techniques have proven successful in evaluating
these changes, allowing for the observation of gross structural changes and
accumulation of disease associated proteins.
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Neuropsychological Assessments

Cognitive Domain

Reference

Alzheimer’s Disease Assessment Scale – Cognitive section
(ADAS-COG)

Memory, Language,
Attention

[68]

Language

[69]

Memory, Visuospatial
Ability

[70]

Memory

[71]

Clinical Progression of
Dementia

[72]

Visuospatial Ability

[73]

Language

[74]

Delis-Kaplan Executive Function System (D-KEFS)

Executive Function

[75]

Mini-Mental State Examination (MMSE)

General Cognition

[76]

Intelligence

[77]

Memory

[78]

Visuospatial Ability

[79]

Memory

[80, 81]

Stroop Task

Executive Function

[82]

Trail Making Test

Attention, ProblemSolving

[83]

Intelligence

[84]

Memory, Attention

[85]

Intelligence

[86]

Boston Naming Test (BNT)
Brief Visuospatial Memory Test—Revised
California Verbal Learning Test (CVLT)
Clinical Dementia Rating (CDR)
Clock Test
Controlled Oral Word Association Test (COWA)

North American National Adult Reading Test (NART)
Rey Auditory Verbal Learning Test (RAVLT)
Rey Complex Figure Test And Recognition Trial (RCFT)
Rey-Osterrieth Complex Figure Test (ROCF)

Wechsler Adult Intelligence Scale (WAIS)
Wechsler Memory Scale (WMS)
Wechsler Test of Adult Reading (WTAR)

Table 1.1.1. Neuropsychological Assessments in AD
Neuropsychological assessments used to diagnose and monitor progression and risk for
AD, including the cognitive domains they aim to measure.
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1.1.3.2.1 Magnetic Resonance Imaging
The most widely utilised Magnetic Resonance Imaging (MRI) technique facilitates the
observation of structural brain changes, in particular brain atrophy, and is considered
important in AD diagnosis. In addition to allowing for the investigation of both the
whole brain structure and specific areas, MRI is widely available, relatively
inexpensive and non-invasive.

MRI global and regional brain volume measures have previously been shown to have
the ability to discriminate between AD, MCI and CN classifications (Figure 1.1.6, [13,
87-90]). Cross-sectional and longitudinal MRI measures have been associated with
conversion from MCI to AD [14, 88, 89, 91-95], and the severity of disease [96].
Further, in studies investigating ongoing disease progression and cognitive decline, the
addition of MRI measures significantly improved the prediction power of the models
containing age, gender and baseline memory scores [97-99]. More recently, measures
of regional brain volume by MRI have been used in healthy elderly populations as a
way of predicting the development of AD before clinical symptomology [100].

1.1.3.2.2 Positron Emission Tomography
Positron emission tomography (PET) is an imaging technique based on the detection of
positron-emitting radioisotopes. Appropriate ligands and radiolabelled isotopes
constitute imaging agents, or tracers, in PET scanning. Commonly used ligands in AD
studies utilise the structure of the hallmark protein aggregates for binding and detection.
Aggregated Ab and Tau form b-sheet secondary structures [102, 103] within which the
aromatic tracers bind [104].
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Figure 1.1.6. Magnetic Resonance Imaging
T1-weighted volume Magnetic Resonance Images (MRIs), in (A) cognitively normal,
(B) mildly cognitively impaired, and (C) Alzheimer’s disease older adults (³ 70 years
old). Image sourced from [101].

Ab, as discussed previously, is the main component of one of the defining hallmarks of
AD. Additionally, it is relatively abundant in the diseased brain [105], has regional
distribution specific to AD, and begins accumulation well before clinical diagnosis
[106]. For these reasons there has been much research into the development and use of
Ab specific PET imaging agents. The first Ab tracer developed, Pittsburgh Compound
B (PiB), consisted of modified thioflavin-T and a carbon-11 (11C) label [107]. Due to
the short half-life of
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C (20 minutes) research has since focused on tracers labelled

with fluorine-18 (18F, 110 minutes, [108]). 18F tracers approved for clinical use include;
florbetapir [109], flutemetamol [110] and florbetaben [111].
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Neocortical Ab-amyloid burden as measured by PET has been consistently correlated
with both post-mortem brain Ab burden [112-117] and CSF Ab42 [118-123]. Further,
brain regions previously associated with increase Ab plaque load (by autopsy or
biopsy), were replicated in PET studies by levels of tracer retention [117, 124-130].
The extent of neocortical Ab burden has been shown to be significantly different
between clinical classifications of CN, MCI and AD (Figure 1.1.7, [110, 131-133]).
Longitudinal studies have reported rates of Ab accumulation from CN or MCI to AD
[134, 135] consistent with the accepted timelines of AD development [106]. Increased
amounts of neocortical Ab has been associated with cognitive decline and brain atrophy
in CN and MCI [136-141].

Figure 1.1.7. Positron Emission Tomography
Positron Emission Tomography (PET) images utilising a 11C Pittsburgh Compound B
(PiB) tracer in cognitively normal, mildly cognitively impaired (MCI), and Alzheimer’s
disease participants. Colour intensity is correlated with the concentration of deposited
amyloid. Image sourced from [142].
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While major research initially focused on the development of tracers for Ab detection,
there has been increased interest in the development of Tau specific tracers. There are
numerous difficulties associated with the development of tracers for Tau including; the
location of Tau aggregation requiring the tracer to cross the blood brain barrier, the low
concentration of Tau aggregates, and Tau aggregation not being specific to AD [143].
Despite these difficulties, a number of Tau tracers have been developed and used in
human trials [144-146]. These tracers have demonstrated the ability to bind to
hyperphosphorylated Tau in the brains of patients with AD [147, 148], and have been
associated with levels of cognitive impairment [147]. Further, there are a number of
tracers in development currently [149, 150]. Like Ab tracers, those used for Tau
detection use both 11C [146] and 18F [144, 145, 149, 150] isotope tags.

1.1.4 Preclinical Disease
The notion of the preclinical AD stage has been investigated since the 1970s when,
through autopsy, neuropathological changes were observed in the brains of
asymptomatic individuals [151, 152]. Broadly, preclinical AD is the long period in
which abnormal neuropathological features accrue while the individual is considered
cognitively normal. In 2013, Villemagne et al. reported that the deposition of Ab occurs
for ~20 years before the clinical diagnosis of AD (Figure 1.1.8, [106]). Further, it has
been observed in both the Harvard Aging Brain Study (HABS) and the Australian
Imaging Biomarker and Lifestyle Study of Aging (AIBL), that ~30% of CN individuals
have significant Ab deposition [153, 154].
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A

B

Figure 1.1.8. Ab Deposition in Alzheimer’s Disease
(A) The distribution of Ab-amyloid (Ab) burden based on clinical classification and
(B) the timeline of Ab deposition. Image sourced from [106]. Healthy control (HC),
Mild cognitive impairment (MCI), Alzheimer’s disease (AD).
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Clinically normal individuals with high Ab burden are more likely to present with
neurodegeneration as measured by hippocampal volume or glucose metabolism [106,
139, 155]. Further, individuals with high Ab burden and/or neurodegeneration are
reported to have impaired cross-sectional and longitudinal cognitive performance [106,
155-157]. A meta-analysis of 38 studies investigating relationships between Ab levels
(CSF or neocortical) and cognition found Ab-related impairment in global cognition,
visuospatial function, processing speed, episodic memory, and executive function
[158]. Additionally, this meta-analysis reported observable decline in global cognition,
semantic memory, visuospatial function, and episodic memory related to Ab burden
[158].

Finally, there have been a number of genetic factors, in particular Apolipoprotein E
(APOE) and Brain Derived Neurotropic Factor (BDNF; both discussed in detail below),
shown to influence preclinical decline. APOE and BDNF have been reported to increase
the rates of cognitive decline and hippocampal atrophy in CN older adults with high
levels of neocortical Ab, both individually (APOE or BDNF; [159-164]) and in
combination (APOE´BDNF; [165]).

Due to these developments in the understanding of preclinical disease, in addition to
the updated diagnostic guidelines, the NIA/AA also published recommended criteria
for different stages of preclinical AD (Figure 1.1.9, [166]). These stages precede MCI
and AD and aim to represent the progression of asymptomatic individuals. Stage 1
includes individuals that demonstrate Ab-accumulation (amyloidosis), as measured by
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Figure 1.1.9. Stages of Preclinical AD
Preclinical AD stages represented graphically. Not all individuals once entering a
preclinical AD stage are expected to progress to the following stage. Imaged sourced
from [166].

CSF biomarkers or PET, in the absence of any additional change in neuropathological
or cognitive changes [166]. Stage 2 involves amyloidosis and measures of
neurodegeneration, including; structural MRI, 18F-fluorodeoxyglucose (FDG) PET (a
measure of glucose metabolism), or elevated levels of CSF tau or phospho-tau [166].
Finally, stage 3 consists of amyloidosis, neurodegeneration, and subtle cognitive
decline that does not yet meet criteria for the diagnosis of MCI [166].
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1.1.5 Risk Factors
Risk factors associated with the development of AD can be separated into 2 categories.
Autosomal Dominant AD (ADAD), is characterised by the inheritance of autosomal
dominant mutations, and accounts for ~1% of all AD cases. ADAD commonly presents
a more aggressive course of disease, and has an early age of onset, usually younger than
65 years. Alternatively, Sporadic AD (SAD), with an age at onset generally older than
65 years, is a complex disease believed to result from the combination of genetic (nonmodifiable), environment and lifestyle (modifiable) factors.

1.1.5.1 Lifestyle
There has been a wide range of modifiable lifestyle risk factors that have been
associated with the development of SAD. These factors include; smoking, diet, sleep
and physical activity. It has previously been reported that smoking is associated with
increased risk of AD [167], and results in increased rates of brain atrophy [168, 169]
and cognitive decline [168]. A risk of AD [170-172] and increased rates of cognitive
decline [172, 173] have been associated with poor adherence to healthy dietary patterns,
a principle example of which is the Mediterranean Diet (MeDi). Briefly, the MeDi can
be characterised by an increased consumption of fruits and vegetables, legumes and
cereals, fish, and unsaturated fatty acids, and decreased consumption of dairy, meat and
poultry, and saturated fatty acids. Further, moderate but regular alcohol consumption,
mostly in the form of wine, also typifies the MeDi. Sleep disturbance has been observed
to increase the risk of AD development and cognitive decline in CN [174, 175]. Finally,
higher levels of physical activity have been associated with a reduction in risk for AD
[176-178], as well as improved longitudinal and cross-sectional cognitive function
[179-181], memory [179] and attention [182].
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1.1.5.2 Genetics
The causative genes implicated in ADAD encode proteins involved in APP processing,
and are associated with alterations in Ab production and aggregation. Alternatively,
genes associated with increased risk of developing SAD have been generally implicated
in a number of biological pathways involved in Ab clearance and processing. The
following book chapter provides in depth information into the genes that have been
implicated in ADAD, SAD and Parkinson’s disease (PD).
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1.3 Polygenic Risk Scores
As discussed in the preceding book chapter, there have been a number of GWAS
identifying variants associated with AD [192, 200, 609-611]. These studies have
reported that individually, the variants identified have small effect sizes for the risk of
developing the late-onset form of AD when compared to the major genetic risk factor,
APOE. To account for their nominal effects, the combination of these gene variants into
a polygenic risk score (PRS) has been employed in various forms.

In general, PRS are calculated by the sum of the risk alleles for all variants, or the sum
of risk alleles weighted by odds ratios or effect sizes [612]. A popular approach in AD
research is the calculation of PRS using the gene variants identified in the
aforementioned GWAS [192, 200, 609-611]. These PRS contain between 3 and 23
variants and have been associated with a range of cognitive and biological disease
markers. Studies investigating un-weighted PRS have evaluated baseline and
longitudinal cognitive change in cognitively normal older adults, and have failed to
identify any significant associations [613-616]. In contrast, when weighting risk alleles
by previously published odds ratios, or beta coefficients, a number of associations with
overall disease risk have been observed. In cohorts investigating CN to AD participants,
PRS weighted by GWAS reported odds ratios, were associated with; incidence of
dementia [443], age of disease onset [617], age related structural brain changes [618],
memory decline [619], and measures of CSF Ab42 [617, 620]. Additionally, in a CN to
AD cohort evaluating a PRS weighted by beta coefficients, associations with diagnostic
status and the severity of MRI measures were identified [324]. Significant associations
between PRS and disease measures have also been identified in preclinical and
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cognitively normal cohorts. In MCI cohorts, PRS weighted by odds ratios were
associated with cognitive decline [621], measures of CSF Tau and phosphorylated Tau
[621], and accelerated progression to AD [622]. Finally, when investigating CN
participants, odds ratio weighted PRS were associated with baseline and longitudinal
cognition [613, 623], hippocampal volume [390, 624], and cortex thickness [625].

In addition to the PRS reported above, others have been reported with altered methods
of variant inclusion and weightings. While focusing on AD-risk genome-wide
significant SNPs is important, it has two potential limitations. The first of these is the
resultant loss of much genetic variance, i.e. the exclusion of genetic variants that are
statistically significant but fail to reach stringent genome-wide significance cut-offs.
To address this first potential limitation, PRS have been developed using an expanded
selection of SNPs that are identified through decreasing the stringency of genetic
association with AD risk. In a study by Mormino et al. an AD-risk weighted PRS, which
set the criteria for inclusion at p=0.01 resulted in the inclusion of ~16,000 SNPs. This
“conservative” PRS, was reported to be associated with baseline and longitudinal
memory and executive function, baseline hippocampal volume, progression to MCI or
AD, and neocortical Ab [626]. Lupton et al. also reported an association between
hippocampal volume and an odds ratio weighted PRS employing a less stringent ADrisk association threshold (p<1´10-4; n(SNPs)=~1000; [627]). Finally, Escott-Price et
al. reported a PRS consisting of ~200,000 SNPs (p£0.5) with an 84% prediction
accuracy for pathology confirmed AD [628]. Further, different methods of risk
evaluation and weighting in PRS have been investigated for the prediction of AD
phenotypes. A PRS of AD-associated variants, weighted by a combination of AD risk

26

and population-based rates of AD, has been associated with individuals age of AD onset
[629].

The second potential limitation of focusing on AD-risk genetic variants is the exclusion
of SNPs that are more associated with pathological or symptomatic (i.e. cognition)
changes than AD-risk. This potential limitation has been far-less explored to date.
However, the combination of two genes previously associated with cognitive decline
has been investigated, namely APOE and Brain Derived Neurotrophic Factor (BDNF).
While APOE is the main genetic risk factor in AD, it is also significantly associated
with rates of cognitive decline [159, 162]. On the other hand, whilst BDNF has been
associated with cognition [161] the AlzGene meta-analysis suggests that it is not risk
factor for AD [630]. The combination of these genetic variants has been shown to
significantly impact Ab-induced cognitive decline. In a cohort of CN older adults with
high levels of brain Ab, those carrying both an APOE e4 and the BDNF met allele
(rs6265) declined cognitively significantly faster when compared to all other groups of
allele combinations [165]. These studies highlight the potential importance of
expanding the genes included in AD PRS from only those associated with AD risk to
those gene variants that have been previously associated with disease phenotypes. This
notion provides the principle theoretical framework for the research undertaken through
the course of this doctoral thesis.
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1.4 Theoretical Framework
In 2014 it was reported by Cummings et al. that of the 413 AD clinical trials performed
between 2002 and 2012, there was only a 0.4% overall success rate [631]. It has been
reported that these failures are due partly to the late disease stage of trial
implementation. This, in addition to the increasing understanding of the extended
preclinical stage of AD, has resulted in greater focus placed on clinical trials being
conducted in the earlier pre-symptomatic disease stages. These trials involve the
identification of at-risk individuals who are expected to decline over the course of the
trial based on brain imaging and CSF biomarkers. However, these biomarkers do not
inform on rates of cognitive change, which remains in most cases the primary outcome
evaluated in trials. It has been observed that in biomarker-positive AD at-risk
individuals there is much variability between individuals in longitudinal measures of
cognition. This results in uncertainty as to whether at-risk individuals selected for trial
inclusion will decline cognitively at rates appropriate for short clinical trials.

In addition to the genetic influence on AD risk outlined in the review above, cognition
has been reported to be highly heritable and polygenic. Combinations of genes
associated with AD-risk based on the large GWAS studies have been associated with
cognitive decline. Further, combinations of genes associated with cognition, namely
APOE and BDNF, have been reported to be associated with longitudinal cognition in
CN at-risk cohorts. As such, genetics could be utilised, in combination with brain
imaging and CSF biomarkers, for the identification of individuals appropriate for
enrolment in clinical trials
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The aim of this thesis was to confirm previously reported associations between ADrisk genes and cognition associated genes with sensitive cognitive composite scores in
a preclinical subset of a highly characterised longitudinal cohort. Further it was aimed
to combine the effects of AD-risk genes and genes associated with cognition in a novel
method that had the ability to appropriately weight genes based on their influence on
the preclinical endophenotypes being tested rather than late stage measures of disease
risk.
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1.5 Hypothesis and Aims

The overarching hypothesis of this thesis is that genetic factors in combination
influence cognitive rates of change in preclinical Alzheimer’s disease.

Aim 1 (Chapter 2):
Assess the impact of genes previously associated with AD risk on measures of
cognition at a preclinical stage.

Aim 2 (Chapter 3):
Assess the effects of genes with a priori evidence for association with cognition on
cognitive rates of change in preclinical AD.

Aim 3 (Chapter 4):
Investigate whether there is a synergistic effect of genes previously associated with
cognition, and further what the best combination of these genes would be.

Aim 4 (Chapter 5):
Determine a method of weighting genes associated with both AD-risk and cognition,
for use in a genetic risk score to improve the prediction of preclinical cognitive rates of
change.
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Chapter 2
Please note that this online copy of the thesis does not contain the complete version
of Chapter 2

CHAPTER 2: Association of a priori candidate, AD-risk
associated, genes with cognitive rates of change in
preclinical AD

2.1 Prologue
As discussed in Chapter 1 (Section 1.3), there have been numerous Polygenic Risk Scores
(PRSs) calculated and subsequently associated with Alzheimer’s disease (AD) related
phenotypes, including AD-related imaging and fluid biomarkers and cognition. In most such
studies, the PRSs that have been calculated have combined AD risk associated genetic variants,
previously identified through genome wide association (GWA) studies (GWAS). These
individual variants are invariably weighted by a measure of AD risk, typically the respective
odds ratios or effect sizes generated from large GWAS, the most common being the
International Genomics of Alzheimer’s Project (IGAP) meta-analysis of GWA data [1].
Presented in this chapter is a replication of this form of PRS in the Australian Imaging,
Biomarkers and Lifestyle (AIBL) Study of Aging. As no AIBL samples were included in the
IGAP meta-analysis, presented here is an independent validation of previous studies.
Specifically, it investigates cognitively normal (CN) individuals in the preclinical stages of
AD.

Previous studies investigating associations between PRS and measures of cognitive decline
have produced varying results, particularly in CN cohorts. The lack of PRS-cognition
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associations reported by some studies could be attributed to sample heterogeneity within the
CN cohort, or the use of cognitive measures not sensitive enough for early in the disease
process. The ensuing study attempts to overcome these limitations, by focusing specifically on
CN older adults who are biomarker positive based on Aβ-amyloid (Aβ) imaging. Further, three
cognitive composite scores are utilised that measure the first cognitive changes occurring in
AD. Through this approach, the first aim of this thesis, to assess the impact of genes previously
associated with AD risk on measures of cognition at a preclinical stage, is addressed.
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Chapter 3
Please note that this online copy of the thesis does not contain the complete version of
Chapter 3

CHAPTER 3: Association of a priori candidate, cognition
associated, genes with cognitive rates of change in
preclinical AD

3.1 Prologue
The results presented in Chapter 2 evidence the potential lack of utility of Alzheimer’s disease
(AD) risk weightings when investigating the association of polygeneic risk scores (PRSs) with
preclinical disease outcomes, such as decline in cognition. When investigating the combinatory
influence of gene variants most commonly associated with the development of AD, significant
associations with rates of cognitive decline in a preclinical cognitively normal population were
only observed with the inclusion of APOE ε4 weighting.

While it was observed that the PRS both with and without APOE were associated with
neocortical amyloid beta (Aβ) burden and CSF-tau, the same was not seen when investigating
longitudinal cognition. This discrepancy in results between disease biomarkers and cognition
could be due to the disease-risk weighting applied to the genetic variants differing from the
actual influence that these variants have on cognitive performance. Further, limiting the
inclusion of single nucleotide polymorphisms (SNPs) in the PRS to those with association with
clinical diagnosis of AD is biased against those variants which may influence the rate of decline
in the preclinical stages of the disease. For example, the non-synonymous rs6265 (Val66Met)
SNP in brain derived neurotropic factor (BDNF) has been reported by the Australian Imaging,
Biomarkers and Lifestyle (AIBL) Study of Aging and others, to be associated with altered rates
of cognitive decline [1-4] but is not amongst the leading AD genetic risk factors and thus has
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been excluded from PRS calculations. A number of genes have previously been associated with
cognitive performance in both AD and CN populations. The studies presented in this chapter
aimed to assess the effects of genes with a priori evidence for association with cognition on
cognitive rates of change in preclinical AD, and determine their potential viability for inclusion
into a polygenic measure.

A review of the literature was conducted to identify genes and genetic variants that have
previously been associated with cognitive performance. The genes that were selected for
inclusion are described below:
•

KIBRA: Kidney and Brain expressed protein, variants within this gene have been
associated with memory performance

•

SPON1: Spondin1, expression of this gene has been associated with improved learning
and cognition

•

COMT: Catechol-O-methyltransferase, non-synonymous variants involved in the
expression of this gene are associated with cognition

•

KL: Klotho, variants within this gene controlling it’s expression have been associated
with aging phenotypes and cognitive performance

Prologue references:
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3.2.1 Abstract
A single nucleotide polymorphism, rs17070145, in the KIdney and BRAin expressed protein
(KIBRA) gene has been associated with cognition and hippocampal volume in cognitively
normal (CN) individuals. However, the impact of rs17070145 on longitudinal cognitive decline
and hippocampal atrophy in CN adults at greatest risk of developing Alzheimer’s disease is
unknown. We investigated the impact rs17070145 has on the rate of cognitive decline and
hippocampal atrophy over six years in 602 CN adults, with known brain Aβ-amyloid levels
and whether there is an interactive effect with APOE genotype. We reveal that whilst limited
independent effects of KIBRA genotype were observed, there was an interaction with APOE in
CN adults who presented with high Aβ-amyloid levels across study duration. In comparison to
APOE ε4-ve individuals carrying the rs17070145-T allele, significantly faster rates of cognitive
decline (global, p=0.006; verbal episodic memory, p=0.004;), and hippocampal atrophy
(p=0.04) were observed in individuals who were APOE ε4+ve and did not carry the
rs17070145-T allele. The observation of APOE effects in only non-carriers of the rs17070145T allele, in the presence of high Aβ-amyloid suggest that carriers of the rs17070145-T allele
are conferred a level of resilience to the detrimental effects of high Aβ-amyloid and APOE ε4.
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3.2.2 Introduction
In cognitively normal older individuals, high levels of neocortical amyloid-b (Aβ-amyloid) are
associated with subtle but detectable cognitive decline [1] and hippocampal atrophy [2]. This
observation is consistent with models of Alzheimer’s disease (AD) which propose a protracted
preclinical phase that could take up to 20 years [3]. This provides a period of opportunity for
understanding, and even interfering with, AD pathogenesis and thus the identification of
biological factors, or trait characteristics, that themselves can influence AD progression has
become of increased importance.

Several genes have been associated with cognitive performance, particularly episodic memory,
and hippocampal atrophy. Previous studies have associated genetic polymorphisms, in
particular apolipoprotein E (APOE) ε2/ε3/ε4 genotype (see review [4, 5]) and the nonsynonymous rs6265 (Val66Met) SNP in brain derived neurotropic factor (BDNF) [6-9], with
altered rates of episodic memory decline and hippocampal atrophy. Decline in measures of
episodic memory, modified by genetic variation, have been reported in both the healthy elderly
[10] and those predicted to be in the early stages of AD based on neocortical Ab-amyloid
imaging [6, 7, 11]. These findings raise the potential that other genetic factors may also
moderate the toxic effects of Ab-amyloid early in AD and contribute to altered rates of
cognitive decline and hippocampal atrophy.

One such candidate is the gene encoding the KIdney and BRAin expressed protein (KIBRA;
sometimes referred to as WW domain-containing protein 1 (WWC1)) [12]. KIBRA is a
cytoplasmic, signal transducer protein expressed mainly in the kidney and brain [13] and in
vitro experiments suggest that, through reduction in postsynaptic levels, it mediates tau induced
memory loss and disruption of synaptic plasticity [14]. This in vitro data is supported through
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genetic studies that report the association of allelic variation in the KIBRA gene with memory
performance, hippocampal atrophy and measurable differences in brain activation.
Specifically, a substitution of C for T in the 9th intron (rs17070145), was initially identified
through a GWAS of verbal episodic memory performance and replicated in two additional
independent cohorts [12]. Episodic memory is one of the earliest cognitive domains to decline,
with previous studies observing decline 4-8 years prior to executive function and up to 7-10
years prior to other cognitive domains [15-17].

However, there is a lack of consensus in subsequent studies that attempted to replicate these
genetic associations with memory performance. Cross-sectional studies of cognitively normal
(CN) older adults, carriage of the rs17070145-T allele has been associated with better
performance in episodic memory [18-22], delayed recall [23-25] and spatial learning [26] and
increased hippocampal volume [20] and activity [19, 24]. Conversely, several studies have
either associated the absence of rs17070145-T with better semantic [27] and long-term [28]
memory, executive function [29] and overall cognitive performance [30] or were unable to
show any association of the SNP with cross sectional episodic memory [29, 31-33] and
hippocampal volume [31] or longitudinal decline in episodic memory and hippocampal volume
[31]. However, common to all these studies is the lack of inclusion of Ab-amyloid imaging,
which may contribute to the lack of consensus due to the impact of underlying Ab-amyloid
burden on cognition not being considered [1, 6, 7, 11].

To address this conjecture requires the availability of comprehensive longitudinal data from
the prospective cohort studies of AD, such as the Australian Imaging, Biomarkers and Lifestyle
(AIBL) Study, which offers the opportunity to retrospectively evaluate candidate biological
factors (e.g. genetic variation) to determine the impact on progression of AD related
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phenotypes, such as cognitive decline and hippocampal atrophy. The AIBL Study has now
more than six years of serial cognitive and neuroimaging assessments, including Ab-amyloid
and structural imaging, in a group of CN adults collected at 18-month intervals. Therefore, the
aim of this study was to characterise, through reporting on 6-years of longitudinal data, the role
of KIBRA rs17070145 allelic variation in this highly characterised CN adult sample and
examine the extent to which this allelic variation is associated with Aβ-amyloid related
cognitive decline and atrophy of the hippocampus. The hypothesis was that CN adults who
carry the rs17070145-T allele would show a slower rate of memory decline and hippocampal
atrophy than those not carrying this allele, though this relationship would be dependent on the
presence of a high brain Aβ-amyloid burden and interact with APOE genotype.
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3.2.3 Methods
3.2.3.1 Participants
This study included 602 CN Caucasian adults enrolled in the AIBL Study, a prospective
longitudinal study of ageing. Information regarding the AIBL Study’s design, enrolment
process, neuropsychological assessments, and diagnostic criteria has been previously described
[34]. The clinical classification of CN, MCI or AD was determined, after clinical review, by a
panel of old age psychiatrists, geriatricians, neurologists, and neuropsychologists who were
blinded to Aβ-amyloid status. Individuals were classified as CN if they did not meet the clinical
criteria for diagnosis of MCI [35] or dementia [36], as described previously [34]. Approval of
the AIBL Study has been granted by each of the ethics committees of each of the member
institutions; Austin Health, St Vincent’s Health, Hollywood Private Hospital, and Edith Cowan
University, and informed written consent was given by all volunteers. All clinical
investigations were conducted in accord with the principles expressed in the Declaration of
Helsinki 1975. All participants were assessed every 18-months. Cognitive, neuroimaging and
laboratory assessment were acquired within 3-months of each other.

3.2.3.2 Cognitive Measures
The neuropsychological test battery administered in the AIBL study has been described in
detail previously [34]. Briefly, it incorporates at each 18-month follow-up, the Mini-Mental
State Examination (MMSE), Clock Drawing Test, California Verbal Learning Test-Second
edition (CVLT-II), Logical Memory I and II (LMI; LMII; Story A only), D-KEFS verbal
fluency, a 30-item version of the Boston Naming Test (BNT), Wechsler Test of Adult Reading
(WTAR) for premorbid IQ, Digit Span and Digit Symbol-Coding subtests of the Wechsler
Adult Intelligence Scale-Third edition (WAIS-III), the Stroop task (Victoria version), and the
Rey Complex Figure Test (RCFT). Resultant data from this battery, in addition to the Clinical
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Dementia Rating (CDR), have been previously used to statistically derive cognitive composites
as previously described [37]. In this study, a verbal episodic memory composite (CDR sum of
boxes (CDRSB), LMII, CVLT false positives (CVLTFP) and long delay free recall (CVLTLDFR)),
and a statistically driven global composite (CDRSB, MMSE, LMII, CVLTFP and Clock), aimed
as a sensitive measure for longitudinal decline in individuals predisposed to AD [37], were
investigated across five study time points: baseline, 18, 36, 54 and 72 months. A correction for
age, gender, years of education, WTAR-estimated premorbid IQ (WAIS-III Full Scale
Intelligence Quotient (FSIQ)) and depressive symptoms (Geriatric Depression Scale (GDS))
was incorporated in the calculation of the cognitive composites [38].

3.2.3.3 Brain Imaging
The 602 CN adults included in this study had undergone Aβ-amyloid imaging, at varying time
points, with PET using 11C-Pittsburgh Compound B (PiB), 18F-florbetapir or 18F-flutemetamol
as previously described [39-41]. PET standardized uptake value (SUV) ratio (SUVR) data was
determined for all tracers using using CapAIBL, a web based freely availably MR-less
methodology [42]. Briefly, SUVs were summed and normalized to either the cerebellar cortex
SUV (PiB), whole cerebellum SUV (florbetapir) or pons SUV (flutemetamol) to yield the
target-region to reference-region SUVR. These SUVRs were then classified as either low
(Αβlow) or high (Αβhigh) Aβ-amyloid burden, based on a tracer-specific SUVR threshold; ≥1.5,
≥1.10 and ≥0.62 for PiB, florbetapir and flutemetamol, respectively, as previously described
[43]. Of these 602 participants, 548 also underwent clinical magnetic resonance imaging
(MRI) for clinical screening and co-registration with PET images. MRI parameters have been
described in detail previously [44]. Briefly, a 3T T1-weighted MRI was performed using the
ADNI magnetization-prepared rapid gradient echo protocol, with an in-plane resolution of 1×1
mm and a slice thickness of 1.2 mm. Hippocampal volume was calculated after correcting for
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age in years and intracranial volume, defined as the sum of grey matter, white matter and
cerebrospinal fluid volumes, as previously described [45].

3.2.3.4 Genotyping
DNA extraction from 5mL of whole blood was performed using QIAamp DNA Blood Maxi
Kits (Qiagen, Hilden, Germany) according to manufacturer’s instructions. TaqMan®
genotyping assays were used to determine APOE (rs7412, assay ID: C____904973_10;
rs429358, assay ID: C___3084793_20) and KIBRA (rs17070145, assay ID: C__33286269_10)
genotypes (Life Technologies, Carlsbad, CA). All TaqMan® genotyping assays were
performed on a QuantStudio 12K Flex™ Real-Time-PCR systems (Applied Biosystems,
Foster City, CA) using the TaqMan® GTXpress™ Master Mix (Life Technologies)
methodology as per manufacturer instructions. KIBRA genotype was observed not depart from
Hardy-Weinberg equilibrium. For the purpose of this study APOE carrier status is defined by
the presence (1 or 2 copies) or absence (0 copies) of the APOE ε4 allele, henceforth referred to
as APOE ε4+ve or APOE ε4-ve, respectively.

3.2.3.5 Statistical Analyses
All statistical analyses were performed using Rstudio (Rstudio Team 2015) Version 0.98.1103
for Macintosh [46]. All analyses were performed based on a dominant model for the KIBRA
rs17070145-T (minor) allele, i.e. T carrier (i.e. C_T and T_T) compared with non-T carrier
(i.e. C_C), as per previous studies [12, 18-21, 24]. Baseline demographic data analyses
provided means, standard deviations, and percentages across the entire PET imaged cognitively
normal sample and stratified by KIBRA rs17070145-T allele carrier (KIBRA-T) and non-carrier
(KIBRA non-T) status. ANOVA (age, premorbid IQ, depressive symptoms) and chi-squared
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tests (gender, years of education, APOE ε4+ve, high Aβ-amyloid burden) were used to
determine the significance of differences between allelic groups. To determine differences in
rates of cognitive change and hippocampal atrophy random intercepts linear mixed-effects
(LME) models were performed using the “nlme” package in R. LMEs were performed due to
their ability to model fixed and random effects, and their robustness when dealing with missing
data [47].

After the inclusion of main effects within the model, i.e. KIBRA genotype, interaction terms
and covariates were included and modelled as described here. Specifically, to investigate the
effect of KIBRA on the rate of cognitive decline and hippocampal atrophy, initially a
KIBRA×Time interaction was modelled across the entire sample, covarying for APOE ε4
carrier and Aβ-amyloid status, with the cognitive composites and hippocampal volume as the
dependent variables. The effect of Aβ status in combination with KIBRA was then investigated
by separately modelling an Aβ×KIBRA×Time interaction, co-varying for APOE ε4 carrier
status. The third analysis focused on only Αβhigh participants, with APOE included within an
APOE×KIBRA×Time interaction. In addition, all analyses for hippocampal atrophy co-varied
for gender. Graphical representations of all models are presented with time dependent standard
error. Further, for all analyses correction for the False Discovery Rate (FDR) using Q-Value
(bootstrap method) was performed [48]. Finally, chi-squared analyses were performed between
groups to ascertain that group differences in rates of decline were not due to disproportionate
rates of clinical conversion over the course of the study.
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3.2.4 Results
3.2.4.1 The effect of KIBRA on cognition and hippocampal atrophy in cognitively normal
adults
A total of 602 CN older adults, defined through the AIBL battery of clinical and
neuropsychological assessments [34] were included in this study. As shown in Table 3.2.1
there were no significant differences or trends between rs17070145 (henceforth referred to
simply as KIBRA) T carriers and non-T carriers at baseline with respect to demographic
variables, premorbid intellect, depressive symptoms, or genotype. In the initial analysis, covaried for APOE ε4 carrier and Aβ-amyloid status (classified by being above (Αβhigh) or below
(Αβlow) Positron Emission Tomography (PET) Aβ-amyloid tracer-specific thresholds) there
were no significant differences in the trajectories between T carriers and non-carriers for
measures of global cognition or episodic memory amongst CN adults (Supplementary Data;
Figure S3.2.3, Table S3.2.4). However, there was a trend towards T-carriers having a mild
improvement (0.028 standard deviations (SD)/year) in both global cognition (non-T carriers, 0.025SD/year; p=0.051) and verbal episodic memory (non-T carriers, -0.019SD/year;
p=0.085), likely due to a practice effect. When evaluating the effect of KIBRA on hippocampal
atrophy in all cases, and co-varying for APOE ε4 carrier and Aβ-amyloid status, no significant
difference (p=0.242) was observed between T carriers (-0.017 cm3/year), and non-T carriers (0.026 cm3/year) over six years (Supplementary Data; Figure S3.2.3, Table S3.2.4). Further, no
significant differences were observed at baseline in any measures of cognition or hippocampal
volume.
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Overall
n = 602

KIBRA T
carrier

KIBRA non-T
carrier

n = 335

n = 267

p

Age (years)

70.79 (6.55)

70.73 (6.49)

70.72 (6.41)

0.9788

Female (%)

334 (55.48)

188 (56.12)

146 (54.68)

0.7871

0-8

48 (8.00)

27 (8.08)

21 (7.89)

9-12

222 (37.00)

127 (38.02)

95 (35.71)

13-15

126 (21.00)

69 (20.66)

57 (21.43)

15+

204 (34.00)

111 (33.23)

93 (34.96)

107.86 (7.23)

107.66 (7.28)

108.14 (7.30)

0.4311

Depressive Symptoms (GDS)

1.05 (1.28)

1.05 (1.35)

1.04 (1.18)

0.9156

APOE ε4 carriage (%)

165 (27.97)

84 (25.53)

81 (31.03)

0.1655

High Aβ-amyloid burden (%)

145 (24.09)

76 (22.69)

69 (25.84)

0.4215

548

301

247

NA

Years of
Education

Premorbid IQ (FSIQ)

MRI (n)

0.9419

Table 3.2.1 Demographic Information
Baseline demographic and clinical characteristics of all imaged cognitively normal adults in
the AIBL study, and based on KIBRA rs17070145 T carriage (T_T and C_T) and non-carriage
(C_C). p values represent statistical significance when comparing T carriage and non-carriage.
GDS, Geriatric Depression Scale; FSIQ, Wechsler Adult Intelligence Scale 3rd Edition (WAISIII) Full Scale Intelligence Quotient.
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No significant differences were observed at baseline in either measure of cognition or
hippocampal volume when investigating the Aβ×KIBRA×Time interaction. Relative to
Αβlow/KIBRA T carriers, the Αβhigh/KIBRA non-T carrier group showed a significantly greater
rate of decline in global cognition (0.037 SD/year; -0.085 SD/year; p=0.008, q=0.036), and the
verbal episodic memory (0.033 SD/year; -0.080SD/year; p=0.012, q=0.042) (Figure 3.2.1,
Table 3.2.2). However, no statistical difference was seen between Αβhigh/KIBRA T carriers and
Αβlow/KIBRA non-T carriers. Analysis of hippocampal atrophy revealed that relative to
Αβlow/KIBRA T carriers (-0.015 cm3/year), the Αβhigh/KIBRA non-T carrier group (-0.055
cm3/year) showed a significantly greater rate of hippocampal atrophy (p=0.002, q=0.034) over
six years (Figure 3.2.1, Table 3.2.2). Likewise, this trajectory of hippocampal atrophy was also
significantly different (p=0.009, q=0.034) relative to Αβlow/KIBRA non-T carriers (-0.017
cm3/year). In contrast, Αβhigh/KIBRA T carriers’ rate of atrophy did not differ from the Αβlow
groups.
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Figure 3.2.1 Rates of change in cognitively normal adults based on KIBRA T carriage and Aβ-amyloid status.
Rates of change are presented for (a) a statistically driven global composite, (b) a verbal episodic memory composite, and (c) hippocampal atrophy
(n=548) in cognitively normal adults (n=602 unless otherwise stated). Αβlow, low Αβ-amyloid burden; Αβhigh, high Αβ-amyloid burden.
Αβlow/KIBRA T carriers (green), Αβlow/KIBRA non-T carriers (blue), Αβhigh/KIBRA T carriers (orange), Αβhigh/KIBRA non-T carriers (red),
controlling for APOE ε4 carrier status. Hippocampal atrophy analysis also controlled for gender (shading represents time dependent standard error,
*p<0.05 when comparing to the Αβlow/KIBRA T carrier group, ^p<0.05 when comparing to the Αβlow/KIBRA non-T carrier group, j p<0.05 when
comparing to the Αβhigh/KIBRA T carrier).
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Αβlow

Αβlow

Αβhigh

Αβhigh

KIBRA T
carrier

KIBRA non-T
carrier

KIBRA T
carrier

KIBRA non-T
carrier

n=259

n=198

n=76

n=69

β

β

β

β

Global

0.037

-0.006

-0.012

-0.085*

Verbal Episodic Memory

0.033

0.0004

0.005

-0.080*

Hippocampal Atrophy

-0.015

-0.017

-0.026

-0.055*^

Table 3.2.2 Group slopes for cognitive composites and hippocampal atrophy in all imaged
cognitively normal participants by KIBRA carrier and Αβ-amyloid status
Group slopes for cognitive composites (presented in SD/year; n=602) and hippocampal atrophy
(presented in cm3/year; n=548) in all imaged cognitively normal participants, controlling for
APOE ε4 carrier status. Αβlow, low Αβ-amyloid burden; Αβhigh, high Αβ-amyloid burden.
*p<0.05 when comparing to the Αβlow/KIBRA T carrier (T_T and C_T) group, ^p<0.05 when
comparing to the Αβlow/KIBRA non-T carrier group, j p<0.05 when comparing to the
Αβhigh/KIBRA T carrier
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3.2.4.2 The effect of KIBRA on cognition and hippocampal atrophy in cognitively normal
adults with high Aβ-amyloid
No significant differences were observed in Αβhigh CN adults at baseline in either measure of
cognition or hippocampal volume when investigating the APOE×KIBRA×Time interaction.
Relative to APOE ε4-ve/KIBRA T carriers, the APOE ε4+ve/KIBRA non-T carrier group
showed a significantly greater rate of decline in global cognition (p=0.006, q=0.034) and verbal
episodic memory (p=0.004, q=0.034) over six years (Figure 3.2.2, Table 3.2.3). Further,
relative to APOE ε4+ve/KIBRA T carriers, the APOE ε4+ve/KIBRA non-T carrier group
showed a nominally significantly greater rate of decline on the verbal episodic memory
composite, however after FDR correction this remained only a strong trend (p=0.018, q=0.055)
over six years (Figure 3.2.2, Table 3.2.3). Hippocampal atrophy analysis revealed that relative
to APOE ε4-ve/KIBRA T carriers (-0.016 cm3/year), the APOE ε4+ve/KIBRA non-T carrier
group (-0.067 cm3/year) had nominally significantly different rates of hippocampal atrophy
however did not survive correction for multiple testing (p=0.040, q=0.107) over six years
(Figure 3.2.2, Table 3.2.3). This trajectory of hippocampal atrophy was suggestive of being
different to APOE ε4-ve/KIBRA non-T carriers (-0.006 cm3/year), however this did not reach
significance (p=0.125), even though this trajectory showed negligible difference to APOE ε4ve/KIBRA T carriers. APOE ε4+ve/KIBRA T carriers’ rate of atrophy did not differ from the
APOE ε4-ve groups. To ascertain that these differences in rates of decline were not due to
disproportionate rates of clinical conversion, the frequency of individuals who converted to
Mild Cognitive Impairment (MCI) or AD over the course of the study was investigated. Within
the APOE ε4+ve group there was no significant difference (p=0.43) between KIBRA non-T
carriers (0.294, 15 out of 41) and KIBRA T carriers (0.294, 10 out of 34) in terms of clinical
conversion.
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Figure 3.2.2 Rates of change in cognitively normal adults with high Aβ-amyloid burden
Rates of change are presented for (a) a statistically driven global composite, (b) a verbal episodic memory composite, (c) hippocampal atrophy in
cognitively normal adults with high Aβ-amyloid (n=145). APOE ε4-negative/KIBRA T carriers (green), APOE ε4-ve/KIBRA non-T carriers (blue),
APOE ε4+ve/KIBRA T carriers (orange), APOE ε4+ve/KIBRA non-T carriers (red). Hippocampal atrophy analysis controlled for gender (shading
represents time dependent standard error, *p<0.05 when comparing to the APOE ε4-ve/KIBRA T carrier group, ^p<0.05 when comparing to the
APOE ε4-ve/KIBRA non-T carrier group, j p<0.05 when comparing to the APOE ε4+ve/KIBRA T carrier).
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APOE ε4-ve

APOE ε4-ve

APOE ε4+ve

APOE ε4+ve

KIBRA T
carrier

KIBRA non-T
carrier

KIBRA T
carrier

KIBRA non-T
carrier

n=38

n=27

n=34

n=40

β

β

β

β

Global

-0.016

-0.014

-0.063

-0.163*^†

Verbal Episodic Memory

-0.008

-0.019

-0.031

-0.146*^j†

Hippocampal Atrophy

-0.016

-0.006

-0.034

-0.067*

Table 3.2.3 Group slopes for cognitive composites and hippocampal atrophy in imaged
cognitively normal adults with high Aβ-amyloid.
Group slopes for cognitive composites (presented in SD/year) and hippocampal atrophy
(presented in cm3/year) in imaged cognitively normal adults with high Aβ-amyloid (n=145).
*p<0.05 when comparing to the APOE ε4-ve/KIBRA T carrier group, ^p<0.05 when comparing
to the APOE ε4-ve/KIBRA non-T carrier group, j p<0.05 when comparing to the APOE
ε4+ve/KIBRA T carrier. †q<0.05 for those reporting nominal significance at p<0.05.
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3.2.5 Discussion
The data reported here support the hypothesis that KIBRA genotype, in combination with APOE
ε4 and Aβ-amyloid, affects rates of memory decline and hippocampal atrophy in cognitively
normal adults. In those CN adults with high Aβ-amyloid burden at baseline, KIBRA non-T
carriers showed significantly faster decline in the statistically driven global composite, and
verbal episodic memory when compared to T carriers with low Aβ-amyloid burden. Within the
subset of CN adults with high Aβ-amyloid burden, we showed that those who are APOE ε4+ve
and KIBRA non-T carriers had significantly faster rates of decline in verbal episodic memory
over 6 years, compared to APOE ε4+ve/KIBRA T carrier and both APOE ε4-ve groups.
Importantly, minimal decline was also observed in the APOE ε4+ve/KIBRA T carrier group,
suggesting that carriage of the KIBRA T allele imparts a level of resilience to negative effects
of APOE ε4 and Aβ-amyloid on memory performance. Further, between group comparisons
of the rates of clinical conversion (CN>MCI/AD) over the course of the study revealed no
significant differences, suggesting that the faster rates of decline were not due to a higher rate
of clinical conversion.

This is further supported by the observations that rates of hippocampal atrophy in this study
also differ based on KIBRA genotype. In CN adults Aβ-amyloid has been previously reported
to be associated with increased hippocampal atrophy [2, 45, 49], however in this study this was
only observed in those individuals who did not possess the KIBRA T-allele, whilst in contrast
KIBRA T-carriers’ rate of atrophy did not significantly differ from the Αβlow groups. In a metaanalysis of APOE neuroimaging studies, hippocampal atrophy has been shown to be increased
in APOE ε4 carriers [5]. Here we report that this association, in a group of Αβhigh CN
individuals, was again only observed in those individuals who did not possess the KIBRA Tallele, whilst in contrast APOE ε4+ve/KIBRA T-carriers’ rate of atrophy did not differ from the
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APOE ε4-ve groups. Taken together, we propose that the KIBRA T allele affords carriers a
level of resilience to the detrimental effects of Aβ-amyloid and APOE ε4 allele on
neurodegeneration, specifically hippocampal atrophy.

The findings presented herein are in line with the original study [12] and subsequent reports
linking the KIBRA T allele with resilience in episodic memory performance [18-21, 24]. The
absence of replication by other studies [27-29, 31-33] may be in part due to the lack of
consistency in the measures of memory decline, whereby varying single neuropsychological
tests, aiming to measure a certain feature of memory or cognition, were used. The use in this
current study of a combination of global and episodic memory composite scores, which
encompass several different tests best associated with a cognitive construct, could also have
contributed to the ability to detect associations with the KIBRA genotype. However, the lack
of inclusion of an assessment of underlying Aβ-amyloid burden in the previous studies may in
fact be the more telling contributor to the lack of consensus on the association of KIBRA with
cognitive performance. The level of neocortical Aβ-amyloid is associated with differential
rates of cognitive decline [1, 50], and this is further altered by genetic factors, in particular
APOE [10, 11] and BDNF [6, 7]. Accounting for the underlying Aβ-amyloid burden in the
current study may have further contributed to the detection of differences in rates of cognitive
decline and hippocampal atrophy reported with APOE ε4 and KIBRA.

Whilst the incorporation of cognitive composites and accounting for underlying Aβ-amyloid
burden is considered a strength of this study, the following limitations of the study are
acknowledged. Firstly, the use of different cognitive tests individually or in combination for
the calculation of domain composites, then those specifically described in this study and using
the methodology described herein, may yield different results. Second, this study included 6-
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years of longitudinal follow-up and validation in other longitudinal cohorts, not undertaken
herein, over longer durations of follow-up, may result in different findings. Third, the
cognitively normal participants in this study were volunteers and not selected at random from
the community, they were generally well educated and performed well on cognitive
assessments and as such the findings presented herein may be applicable only to similar
cohorts. Fourth, there is an overlap between those who are Aβhigh and those who are APOE
ε4+ve, which could confound the results when looking at their interaction. Finally, the KIBRA
T-allele’s previously reported association with altered brain activation using functional MRI
(fMRI) [12, 19] could not be tested due to the lack of fMRI data, under a non-resting state, in
the AIBL Study.

Studies have previously demonstrated the main areas of KIBRA expression in the brain are
those also that are implicated in memory function, the hippocampus and temporal cortex [12,
51]. Furthermore, increased KIBRA gene expression in the temporal cortex [52] and
hippocampus [22] has been associated with late onset AD. However, in a recent post-mortem
brain transcriptomic study in neuropathogically normal individuals by Piras and colleagues a
trend towards increased KIBRA gene expression was observed in KIBRA T homozygotes [53].
Further quantitative PCR analysis reported an over-expression in T-homozygotes compared to
C-homozygotes in the hippocampus [53]. Further, the transcriptomic analysis revealed
differential activation of the mitogen-activated protein kinase (MAPK) pathway [53], a
pathway important in learning and memory processes, suggesting a potential mechanism
underpinning a decline in memory performance reported in this study. It has also been shown
that there is increased hippocampal activity in episodic memory performance tasks in KIBRA
T carriers when compared with non-T carriers [19], consistent with the notion of protection
from memory decline. KIBRA T allele carriers have also been shown to have a decreased levels
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of brain activation compared to non-T allele carriers in several hippocampal regions activated
during memory retrieval [12]. The authors hypothesised that individuals who do not carry the
T allele require a greater level of hippocampal activation for memory retrieval [12].

In addition to the association studies described above, recent in vivo evidence provides
molecular insights into mechanisms by which KIBRA is involved in memory performance.
Synaptic plasticity, which is altered in AD, is modulated by dendrin, which in turn binds to the
protein that KIBRA encodes (KIBRA; see review [54]). Further, KIBRA protein contains a
protein kinase C (isoform ζ; PKCζ) binding domain [55] and has been reported to co-localise
with protein kinase M (isoform ζ; PKMζ) [56], a brain specific variant of PKCζ, which plays
important roles in memory formation and long-term potentiation. Johannsen et al have shown
the function of the KIBRA protein to be regulated by its C2 domain [51], which is required for
Ca2+ binding and is therefore involved in signal transduction in the neurons. This regulation is
hypothesised to mediate the effect of the KIBRA protein on memory formation [51]. In a recent
study, Tracy and colleagues have proposed a novel mechanism by which acetylated tau
associated memory loss and disruption of synaptic plasticity is mediated by a reduction in
postsynaptic KIBRA protein [14]. This finding links the previous reports of reduced KIBRA
gene expression in AD with a biological mechanism mediated by acetylated tau. Whether the
KIBRA T allele affords a level of resilience to this loss of synaptic plasticity remains to be
determined.

Our findings indicate that KIBRA rs17070145 genotype, when combined with high brain Aβamyloid burden and APOE ε4 carriage, modifies longitudinal rates of decline in verbal episodic
memory, a global cognitive composite and hippocampal volume. We propose that early in the
disease process of AD, carriers of the KIBRA T-allele are conferred a level of resilience to Aβ-
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amyloid and APOE ε4 driven decline. The potential mechanisms by which KIBRA contributes
to synaptic plasticity, and AD progression warrant further investigation, including the potential
impact on Aβ-amyloid accumulation, and may reveal novel pathways contributing to
neuroprotection/neurodegeneration. Our results also highlight the potential application of
genetics for risk stratification when designing clinical trials, particularly those that employ Aβamyloid imaging for screening. The nature of the effects of genetic variations, specifically
assessing the combined effect(s) of additional genes affecting cognitive performance would
have merit in such settings and requires further investigation.
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3.2.11 Supplementary Data

Figure S3.2.3 Rates of change in cognitively normal adults based on KIBRA T carriage.
Rates of change are presented for (a) a statistically driven global composite, (b) a verbal episodic memory composite, (c) hippocampal atrophy
(n=548) in cognitively normal adults (n=602 unless otherwise stated). KIBRA T carriers (grey) and non-T carriers (black), controlling for APOE
ε4 carrier and Aβ-amyloid status. Hippocampal atrophy analysis also controlled for gender (shading represents time dependent standard error, *
p<0.05).
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KIBRA T carrier

KIBRA non-T carrier

β

β

p

Global

0.028

-0.025

0.051

Verbal Episodic Memory

0.028

-0.019

0.085

Hippocampal Atrophy

-0.017

-0.026

0.242

Table S3.2.4 Group slopes for cognitive composites and hippocampal atrophy in all imaged
cognitively normal participants by KIBRA carrier status
Group slopes for cognitive composites (presented in SD/year; n=602) and hippocampal atrophy
(presented in cm3/year; n=548) in all imaged cognitively normal participants, controlling for
APOE ε4 carrier and Aβ-amyloid status. *Represents a nominally statistically significant
difference in slope of the KIBRA non-T carrier (C_C) group when compared to the KIBRA T
carrier (T_T and C_T) group.
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3.6 Epilogue
The preceding studies presented in this chapter aimed to investigate the effect of variants within
a targeted set of genes, with a priori evidence of association with cognitive performance, on
cognition in a preclinical AD cohort. When investigating the KIBRA and SPON1 variations,
no independent associations were observed with cognitive composite measures. However, after
interaction with APOE e4 in individuals with high levels of neocortical amyloid beta (Aβ)
significant associations were observed. No significant associations were observed,
independently or with interaction, when investigating KL or COMT. Taken together the studies
presented in this chapter, along with previous associations of BDNF with preclinical cognitive
decline, provide strong evidence to support the inclusion of genetic variants over and above
those associated with the clinical diagnosis of AD in polygenic risk scores (PRSs). Further, the
biased inclusion of AD risk variants may potentially be at the detriment of the performance of
the PRS, particularly in the prediction of cognitive decline in preclinical AD.

Although significant associations were observed for a subset of variants studied, these analyses
were in isolation and as such does not completely discount the influence of these variants.
Specifically, the contribution of a genetic variant to influencing preclinical cognitive decline
may be apparent when considered in combination with other variants rather than as an
independent effect. The next chapters explore different methods of combining these variants.
In Chapter 4, genetic variants associated with cognitive decline are combined. Then, in Chapter
5, an approach is taken to combine both cognitive performance and AD risk associated variants
such that it would allow for the accurate prediction of cognitive decline in preclinical AD.
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CHAPTER 4: Assessing the utility of combining a priori
candidate, cognition associated, genes for predicting
cognitive decline in preclinical AD.

4.1 Prologue
The studies presented in Chapter 3 provided the characterisation of a targeted selection of genes
with a priori evidence of association with cognitive performance.

Specifically, the

independent and interactional effects (with APOE e4) of the cognitive gene variants on rates
of cognitive decline were explored in cognitively normal older adults in the Australian Imaging
Biomarkers and Lifestyle (AIBL) Study of Aging. These studies were the first to investigate
the influence of these genetic variants on cognition in a preclinical Alzheimer’s disease (AD)
cohort, defined using Aβ-Amyloid (Aβ) brain imaging.

Of the four candidates investigated in Chapter 3, two reported to have significant associations
with longitudinal cognitive performance. That is, in cognitively normal individuals with high
levels of neocortical Aβ and carrying at least one copy of the APOE e4 allele, variants within
SPON1 and KIBRA were associated with significantly difference rates of cognitive decline.
Conversely, when investigated KL and COMT gene variants were not associated with
differences in cognitive performance, even after interaction with Aβ burden and APOE e4
carriage. Whilst the preceding studies did not present significant associations across all genes
investigated, it is still plausible that individual genes may have subtle effects on cognitive
decline in the preclinical stages of AD that are more apparent when studied in combination
with other genes.
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The ensuing study presented in this chapter hypothesized that cognitive genes could have an
additive influence that is obviously not observed when investigating variants independently.
To address this hypothesis, the study aimed to address the third aim of the thesis, being to
investigate whether there is a synergistic effect of genes previously associated with cognition,
and further what the best combination of these genes would be.

To achieve this aim it was proposed to combine genes associated with cognitive performance
using a method that would be simple to use and replicate, allowing for ease of use clinically.
In addition to the genes investigated in Chapter 3, the Val66Met variant in BDNF, previously
studied in the AIBL cohort [1, 2], and a variant within the “CUB and Sushi Multiple Domains
1” (CSMD1) gene were included. CSMD1 is involved in complement regulation and variants
within it have been associated with cognitive performance in healthy individuals [3, 4]. A
decision tree approach was undertaken to derive groups based on rates of cognitive decline,
specifically decline in a composite measure of verbal episodic memory in cognitively normal
individuals with high levels of brain Aβ.
Prologue References:
1.

Lim, Y.Y., et al., BDNF Val66Met, Abeta amyloid, and cognitive decline in preclinical
Alzheimer's disease. Neurobiol Aging, 2013. 34(11): p. 2457-64.

2.

Lim, Y.Y., et al., APOE and BDNF polymorphisms moderate amyloid beta-related cognitive
decline in preclinical Alzheimer's disease. Mol Psychiatry, 2015. 20(11): p. 1322-8.
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4.2.1 Abstract
INTRODUCTION: In cognitively normal (CN) older adults, high levels of Aβ-amyloid are
associated with significant decline in cognition, especially episodic memory. Several genes
have previously been associated with cognition, including APOE, KIBRA, KLOTHO, BDNF,
COMT, SPON1 and CSMD1. While some of this variation has been attributed to some of
these genes individually, the combined effects of these genes on rates of cognitive decline,
particularly in preclinical Alzheimer’s Disease remain largely unknown.
METHODS: To elucidate if risk alleles within these genes can be suitably combined to
predict cognitive decline 127 CN older adults with elevated PET-ascertained Aβ-amyloid
were included in a decision tree analysis to define a “cognitive gene risk profile” for decline
in a verbal episodic memory composite.
RESULTS: The episodic memory-derived cognitive gene risk profile defined four groups:
APOE ε4+ Risk, ε4+ Resilient, ε4- Risk, ε4- Resilient, with the ε4+ Risk group declining
significantly faster than all other groups (ε4+ Resilient, p=0.0008; ε4- Risk, p=0.025;
ε4- Resilient, p=0.0006). The ε4+ Risk group also declined significantly faster than all other
groups on Global, Clinical Progression and Pre-Alzheimer’s cognitive composites.
DISCUSSION: The defined cognitive gene risk profile has potential utility in participant
selection/stratification for preclinical AD trials that incorporate Aβ-amyloid and where
decline in cognition is essential to determine therapeutic effectiveness.

KEY WORDS: genetic risk profiles, cognitive decline, Alzheimer’s disease, episodic
memory, Ab-amyloid
NON-STANDARD ABBREVIATIONS: AIBL, Australian Imaging Biomarkers and
Lifestyle study of Ageing; CN, Cognitive Normal; Cog-GRP, Cognitive Gene Risk Profile;
PACC, Pre-Alzheimer’s Cognitive Composite
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4.2.2 Introduction
Evidence from prospective longitudinal cohort studies suggests that the pathological changes
in Alzheimer’s Disease (AD) commence decades before the onset of clinical symptomology
[1]. Further, it has been established that higher levels of Aβ-amyloid (Aβ) in cognitively
normal (CN) older adults is associated with accelerated decline in cognition [2]. As such,
cerebrospinal fluid (CSF) and imaging biomarkers of Aβ are used to define the preclinical stage
of AD [3, 4]. However, at the preclinical stage of AD there is considerable interpersonal
variability in the rate of cognitive decline, suggesting that while Aβ is a necessary condition
for AD, other factors influence the relationship between this biomarker and clinical disease
progression. Cognition has been shown to be both highly heritable and highly polygenic [5]
and allelic variation in several genes associated with cognition has been shown to explain some
variation in cognitive function in older adults and in Aβ related cognitive decline in early AD
[6-8]. Thus suggesting that genetics could help inform and predict rates of cognitive decline,
and identify groups of CN older adults that are at a higher risk of a more rapid decline in
cognition.

There have been several individual genes associated with cognitive performance and decline.
The major genetic risk factor for AD, the ε4 allele of apolipoprotein E (APOE) [9], has been
consistently associated with accelerated rates of episodic memory decline and hippocampal
atrophy (reviewed in [10]). The non-synonymous rs6265 (Val66Met) single nucleotide
polymorphism (SNP) in the brain derived neurotropic factor (BDNF), has been linked with
altered rates of decline in several cognitive domains, and hippocampal atrophy [7, 8]. A further
non-synonymous SNP that regulates dopamine availability in the central nervous system,
rs4680 (Val158Met) within Catechol-O-methyltransferase (COMT), has also been associated
with cognitive performance [11]. The Klotho gene (KL), initially discovered in transgenic mice
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with a phenotype resembling human aging [12], has a functional variant, KL-VS that has been
associated with life expectancy [13], global cognition [14], processing speed [14], and brain
volume [15].

A further gene, KIBRA, that encodes the KIdney and BRAin expressed protein has recently
been shown to be involved in the mediation of tau-induced memory loss and synaptic plasticity
[16]. Allelic variation in the KIBRA gene, specifically a substitution of C for T in the 9th intron
(rs17070145), has been reported to be associated with memory performance [17], hippocampal
atrophy [18] and measurable differences in brain activation [17]. We have described recently
how this gene contributes to moderating Aβ driven cognitive decline [19]. Additionally, several
SNPs in the CSMD1 (CUB and Sushi Multiple Domains 1) gene, involved in the regulation of
complement and inflammation [20], have been associated with episodic memory and general
cognition in a cognitively normal sample [21]. Finally, multiple SNPs within the Spondin 1
(SPON1) gene, involved in the processing of amyloid precursor protein (APP) [22], have been
associated with disease severity [23] and rates of cognitive decline [24], though only in AD
individuals.

Several studies have investigated the extent to which combinations of genes can influence
cognitive decline and clinical progression in AD [25-28]. However, most of these studies
focused on genes shown previously to be associated with risk for AD, with gene weighting
based on AD risk [25, 26]. Thus these polygenic approaches may have resulted in exclusion of
genes associated with cognitive performance, or if included, their influence diluted due to a
disease risk based weighting [26]. Further, few studies have taken brain Aβ burden into
consideration and investigated combining genes associated with cognitive performance in
preclinical AD [8, 29].
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This study hypothesised that combining genes shown to be associated with cognition would
explain variance in Aβ related cognitive decline in preclinical AD. This study aimed to
combine these genes into a straightforward profile able to discriminate individuals based on
cognition, and particularly episodic memory, which is one of the earliest cognitive domains to
decline [30]. The profile was created in CN older adults, signified at risk of cognitive decline
based on brain imaging biomarkers, enrolled in the Australian Imaging, Biomarkers and
Lifestyle (AIBL) Study. Extensive 18-monthly assessment, including cognitive and
neuroimaging, within the AIBL Study allows for the longitudinal evaluation of this profile.
Such a genetic profile could be easily implemented for the identification of individuals with
accelerated rates of cognitive decline, which could have utilisation for clinical trial design,
leading to more efficient clinical trials and secondary prevention studies.
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4.2.3 Materials and Methods
4.2.3.1 Study Participants
One hundred and thirty-three CN biomarker positive (based on brain imaging) older adults
enrolled in the AIBL Study, a prospective longitudinal study of ageing, were included in this
study. The study design, enrolment process, neuropsychological assessments, and diagnostic
criteria of the AIBL Study have been previously described [31]. Approval of the AIBL Study
has been granted by each of the ethics committees of each of the member institutions: Austin
Health, St Vincent’s Health, Hollywood Private Hospital, and Edith Cowan University, and all
volunteers gave informed written consent. Assessments occurred every 18 months, with
cognitive, neuroimaging and laboratory assessment achieved within 3 months of each other.

4.2.3.2 Cognitive Measures
Burnham et al. previously calculated cognitive composite scores using the AIBL
neuropsychological test battery and the Clinical Dementia Rating (CDR) scale [32]. These
composite scores were used in this study to assess cognitive performance. The AIBL
neuropsychological test battery consists of Mini-Mental State Examination (MMSE), Clock
Drawing Test, California Verbal Learning Test-Second edition (CVLT-II), Logical Memory I
and II (LMI; LMII; Story A only), D-KEFS verbal fluency, a 30-item version of the Boston
Naming Test (BNT), Wechsler Test of Adult Reading (WTAR), Digit Span and Digit SymbolCoding subtests of the Wechsler Adult Intelligence Scale-Third edition (WAIS-III), the Stroop
task (Victoria version), and the Rey Complex Figure Test (RCFT) [31]. Briefly, a verbal
episodic memory composite (CDR sum of boxes (CDRSB), LMII, CVLT-II recognition false
positives (CVLTFP) and long delay free recall (CVLTLDFR)) was used as the primary cognitive
measure for defining groups with different rates of decline. Groups defined by decline in
episodic memory were also assessed against a global cognition composite (CDRSB, MMSE,
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LMII, CVLTFP and Clock), and a composite measure of clinical progression (CDRSB, MMSE)
[32]. In addition, the Pre-Alzheimer’s cognitive composite (PACC) previously calculated by
Donohue et al. was also investigated [33]. In the calculation of the statistically driven
composites there were corrections for age, sex, years of education, premorbid IQ (WTARestimated WAIS-III Full Scale Intelligence Quotient (FSIQ)) and depressive symptoms
(Geriatric Depression Scale (GDS)) [34]. Five cognitive assessment time points were used:
baseline, 18, 36, 54 and 72 months.

4.2.3.3 Brain Imaging
Aβ imaging with positron emission tomography (PET) using
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C-Pittsburgh Compound B

(PiB), 18F-florbetapir or 18F-flutemetamol was performed on the 133 cognitively normal adults
included in this study as previously described [35-37]. The same region of interest template
was used to determine PET standardized uptake value (SUV) ratio (SUVR) data for all tracers
[38]. Briefly, SUVs were summed and scaled based on tracers PiB, florbetapir, and
flutemetamol, to the cerebellar cortex, whole cerebellum or pons, respectively, to yield the
target-region to reference-region SUVR. This study classified participants as high (Αβhigh) Aβ
burden, based on a tracer-specific SUVR threshold; ≥1.5, ≥1.10 and ≥0.62 for PiB, florbetapir
and flutemetamol, respectively, as previously described [39]. For cross-sectional comparison
of Aβ burden with multiple tracers a linear regression transformation was applied to

18

F-

labbelled tracers to generate PiB-like SUVR units termed the “Before the Centiloid Kernel
Transformation” (BeCKeT) scale [40].
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4.2.3.4 Genotyping
We have previously described methods of DNA extraction and SNP genotyping [41]. Briefly,
manufacturer’s instructions were followed to extract DNA from 5mL of whole blood using
QIAamp DNA Blood Maxi Kits (Qiagen, Hilden, Germany). TaqMan® genotyping assays
were used to determine APOE (rs7412, assay ID: C____904973_10; rs429358, assay ID:
C___3084793_20), BDNF (rs6265, assay ID: C__11592758_10), KIBRA (rs17070145, assay
ID: C__33286269_10), COMT (rs4680, assay ID: C__25746809_50), KL (KL-VS; rs9536314,
assay ID: C___2983037_20; rs9527025, assay ID: C___2983036_20), SPON1 (rs11023139,
assay ID: C_____55174_30), and CSMD1 (rs2740931, custom designed assay) genotypes
(Life Technologies, Carlsbad, CA). TaqMan® genotyping assays were performed on a
QuantStudio 12K Flex™ Real-Time-PCR systems (Applied Biosystems, Foster City, CA)
using the TaqMan® GTXpress™ Master Mix (Life Technologies) as per manufacturer
instructions. APOE carrier status is defined by the presence (1 or 2 copies) or absence (0 copies)
of the APOE ε4 allele, henceforth referred to as APOE ε4+ve or APOE ε4-ve, respectively.
Further KL-VS homozygotes (n=6) were excluded from all analyses resulting in the inclusion
of 127 CN adults.

4.2.3.5 Statistical Analysis
All statistical analyses were performed using Rstudio (Rstudio Team 2015) Version 0.98.1103
for Macintosh [42]. Baseline demographic data analyses, using the generic functions of the R
“base” package, provided means, standard deviations, and percentages across the cognitively
normal sample. The first stage of analysis was the definition of the individual slopes for verbal
episodic memory decline in the Αβhigh sample (n=127), which would then be included in the
subsequent decision tree analysis. These individual slopes were created using the “nlme”
package in R using random intercepts linear mixed-effects (LME) models, which model fixed
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and random effects, and deal with missing data robustly [43]. In this analysis, a verbal episodic
memory × time interaction was modelled to generate per person β values (slopes). As the
calculation of the verbal episodic memory composite is controlled for age, sex, years of
education, premorbid IQ and depressive symptoms, no further covariates were included in the
LME models. The second stage of analysis utilised these slopes (dependent variables) in
combination with the seven genes of interest (APOE, BDNF, KIBRA, KL, COMT, SPON1 and
CSMDI; independent variables), in a decision tree model using the “rpart” package in R, to
define the “Cognitive Gene Risk Profile” (Cog-GRP) groups to be used in subsequent analyses.
The final stage of analysis was to assess the performance of the defined Cog-GRP groups. To
achieve this differences in rates of cognitive change between these groups were assessed using
random intercepts LME models, using the “nlme” package in R. Specifically, a Cog-GRP
group × Time interaction was modelled across the entire sample, with the cognitive composites
as the dependent variables. With the exception of analyses for the AIBL-PACC, which covaried for age, no additional covariates were included due to their inclusion in the generation
of the cognitive composites. All LME models were presented graphically with time point
dependent standard error. Effect sizes were calculated based on cognitive performance at the
sixth year of follow-up using the “effsize” package in R.
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4.2.4 Results
4.2.4.1 Aβhigh cognitively normal adults baseline demographics, genotype frequencies and
cognitive slopes
Table 4.2.1 shows the demographics, genotype frequencies and cognitive slopes of the 127
Aβhigh CN older adults included in the study. The statistically driven global composite (-0.0901
SD/year), clinical progression (-0.0484 SD/year), and verbal episodic (-0.0774 SD/year)
composites all presented with a negative rate of change when investigating Aβhigh CN older
adults.

4.2.4.2 Defining the Cognitive Gene Risk Profile (Cog-GRP) and group stratification
The “Rpart” package in R was used to calculate the decision tree that defined the Cog-GRP.
The decision tree was constructed using 7 gene variants (APOE ε4+/ε4-, BDNF Met+/Val/Val,
KIBRA T-/T+, COMT Val+/Met/Met, KLOTHO VS-/VS+, SPON1 A-/A+, and CSMD1 G-/G+)
against a composite score of verbal episodic memory in an Aβhigh sample. The analysis resulted
in the selection of six of the seven genes (COMT falling out of the analysis, Figure 4.2.1a),
which were used to classify the participants into 8 groups. Due to small sample sizes in the
resultant 8 groups, groups were collapsed at the end of the respective ε4+ and ε4- branches.
This was based on their same directions, and similar rates, of change (SD/year) in verbal
episodic memory over the assessed 6-years. The resulting 4 groups were then classified as “at
risk” or “resilient” based on carriage of the ε4 allele and differences in decline on the verbal
episodic composite for these collapsed groups were reconfirmed (Figure 4.2.1b). The ε4+ Risk
(-0.1891 SD/year) group had a significantly faster rate of decline than ε4+ Resilient (0.0014
SD/year; p=0.0008; At 6th year: Cohen’s d=1.48, 95% CI 0.91-2.02), ε4- Risk (-0.0749
SD/year; p=0.025; At 6th year: Cohen’s d=1.14, 95% CI 0.67-1.59) and ε4- Resilient (0.0097
SD/year; p=0.0006; At 6th year: Cohen’s d=2.37, 95% CI 1.63-3.04) groups and reached
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clinically significant thresholds of cognitive impairment (performance at 1.5 standard
deviations below controls, dashed line Figure 4.2.1b) after 5 years. For comparison purposes,
Figure 4.2.1b, shows that this threshold is crossed at approximately 9.6 years when only
carriage of the APOE e4 allele is considered, which had a decline of -0.110 SD/year.

116

Aβhigh CN older adults
Age (years)

73.17 (6.50)

Female (%)

66 (51.97)
0-8

11 (8.66)

Years of
Education

9-12

51 (40.16)

(%)

13-15

31 (24.41)

15+

34 (26.77)

Premorbid IQ (FSIQ)

108.54 (6.87)

Depressive Symptoms (GDS)

1 (1.26)

APOE (% ε4+ve)

66 (51.97)

BDNF (% Met+ve)

43 (33.86)

KIBRA (% T–ve)

62 (48.82)

KL (%VS–ve)

99 (77.95)

COMT (% Val+ve)

103 (81.10)

CSMD1 (% G–ve)

42 (33.07)

SPON1 (% A–ve)

112 (88.19)

Global Cognition*

-0.0901

Clinical Progression*

-0.0484

Verbal Episodic Memory*

-0.0774

AIBL-PACC†

-0.1144

Table 4.2.1 Baseline demographic information
Baseline demographic, genotype frequencies and cognitive composites slopes for cognitively
normal (CN) older adults with high Aβ-amyloid (Aβhigh) in the AIBL Study (n=127).
*Cognitive composites presented in SD/year, and the †Pre-Alzheimer’s Cognitive Composite
(AIBL-PACC) presented in 4×SD/year. AIBL-PACC controlled for age. KL-VS homozygotes
excluded (n=6). GDS, Geriatric Depression Scale; FSIQ, WTAR-estimated FSIQ.
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Figure 4.2.1 Cognitive Gene Risk Profile (Cog-GRP)
(a) Derivation of the cognitive gene risk profile (Cog-GRP) within cognitively normal adults
high Aβ-amyloid (Aβhigh; n=127) using decision tree analysis. Defining four groups ε4+ Risk
(red, n=40), ε4+ Resilient (orange, n=26), ε4– Risk (blue, n=43), ε4– Resilient (green, n=18).
Values represent SD/year change in the verbal episodic memory composite. All analyses
were corrected for age, sex, years of education, premorbid IQ and depressive symptoms. (b)
Confirmation of performance of collapsed groups identified by the Cog-GRP in Aβhigh
cognitively normal adults (n=127) and comparative performance of APOE when considered
independently. ε4– Resilient group (green line), ε4– Risk group (blue line), ε4+ Resilient
group (orange line), ε4+ Risk group (red line), APOE ε4-ve (grey dotted line), APOE ε4+ve
(black dotted line). Broken black line represents 1.5 SD of decline. Error bars represent time
dependent standard error, *p<0.05 when comparing to the ε4+ Risk group
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4.2.4.3 Performance of Cog-GRP groups on cognition in cognitively normal adults
When investigating the association between Cog-GRP groups and cognition in Aβhigh CN older
adults, no significant differences were observed at baseline in any composite measures. The
ε4+ Risk group showed a significantly greater rate of decline on the global composite
(p=0.00009), clinical progression composite (p=0.0003) and AIBL-PACC (p=0.0022), over six
years when compared to ε4- Resilient group (Table 4.2.2, Figure 4.2.2). At the 6th year of
follow-up there was a large effect observed for the global (Cohen’s d=2.57, 95% CI 1.82-3.26)
and clinical progression composites (Cohen’s d=1.87, 95% CI 1.20-2.50) and AIBL-PACC
(Cohen’s d=2.32, 95% CI 1.60-2.99). Further, relative to the ε4- Risk and ε4+ Resilient groups,
the ε4+ Risk group also showed a significantly greater rate of decline on the global composite
(p=0.020, p=0.001), and clinical progression (p=0.023, p=0.015) over six years (Table 4.2.2,
Figure 4.2.2). Large effects were again observed at the 6th year of follow-up for both the global
(ε4- Risk: Cohen’s d=1.18, 95% CI 0.70-1.63; ε4+ Resilient: Cohen’s d=1.52, 95% CI 0.942.06) and clinical progression composites (ε4- Risk: Cohen’s d=0.95, 95% CI 0.48-1.39; ε4+
Resilient: Cohen’s d=1.27, 95% CI 0.72-1.79). The ε4+ Risk group also declined significantly
faster on the AIBL-PACC (p=0.040) when compared to the ε4– Risk group (at 6th year,
Cohen’s d=1.18, 95% CI 0.70-1.63), though only a trend toward significance, (p=0.073), when
comparing to the ε4+ Resilient group. Across all cognitive composites there was no significant
difference between groups in terms of baseline cognitive performance, with the exception of
the extremes of ε4+ Risk compared to ε4- Resilient groups in the Global cognitive composite
(Table 4.2.2). Finally, mean Aβ burden was observed to be significantly different between CogGRP groups (ε4+ Risk, 2.02±0.35; ε4+ Resilient, 1.85±0.21; ε4- Risk, 1.82±0.24; ε4- Resilient
1.97±0.46; F= 3.41, p=0.020); though this was driven only by a difference between ε4+ Risk
and ε4- Risk groups (Post-hoc Bonferroni, p=0.026). Finally, when analyses were repeated in
397 Aβlow CN older adults from the AIBL study, to determine whether the defined Cog-GRP
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had utility in defining cognitive decline in in biomarker negative CN older adults, no significant
differences at baseline or between slopes in any composite measures were observed (see
Section 4.2.8 Supplementary Data, for full sample demographics and analysis outcome
measures in Aβlow CN older adults; Tables S4.2.3 and S4.2.4).

ε4+ Risk group

ε4+ Resilient group

ε4– Resilient
group

ε4– Risk group

a

β

a

β

a

β

a

β

Global

-0.578

-0.218

-0.385

-0.019*

-0.284

-0.089*

0.291*

0.030*

Clinical Progression

-0.087

-0.100

0.048

-0.032*

-0.029

-0.042*

0.079

0.006*

AIBL-PACC

7.168

-0.334

8.349

-0.072

7.982

-0.066*

8.603

0.126*

Table 4.2.2 Group intercepts and slopes for cognitive composites in Aβhigh CN older adults
Group intercepts (a; as SD) and slopes (β; as SD/year) for cognitive composites (presented in
SD/year) and AIBL-PACC (presented in SD×4/year) in imaged cognitively normal (CN) older
adults with high Aβ-amyloid (Aβhigh; n=127). *p<0.05 when comparing to the ε4+ at Risk
group.
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Figure 4.2.2 Cognitive rates of change in Aβhigh CN older adults
Cognitive rates of change are presented for a (a) global composite, (b) clinical progression composite, and (c) Pre-Alzheimer’s Cognitive
Composite (AIBL-PACC) in cognitively normal (CN) older adults with high Aβ-amyloid (Aβhigh; n=127). ε4– Resilient group (green line), ε4–
Risk group (blue line), ε4+ Resilient group (orange line), ε4+ Risk group (red). AIBL-PACC controlled for age. Error bars represent time dependent
standard error, *p<0.05 when comparing to the ε4+ Risk group.
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4.2.5 Discussion
Results from this study support the hypothesis that combining genes previously
associated with cognitive performance allows for the identification of groups of
individuals with accelerated rates of cognitive decline. In CN older adults with high Aβ
burden at baseline a decision tree was created driven by decline in a composite score of
verbal episodic memory to define a Cog-GRP. This profile combined the effects of
APOE, BDNF, KIBRA, KLOTHO, SPON1 and CSMD1. COMT dropped out of the
model due to lack of influence in discriminating the cognitive change within the sample.
There is no association between COMT individually and rates of cognitive decline in
this population (data not shown), so it is unsurprising that it has not contributed to the
genetic risk profile created. Due to the lack of significant difference in decline and the
small sample size between the groups at either extreme of the Cog-GRP these groups
were collapsed to 4 overall classifications. These classifications were described based
on carriage of the APOE ε4 allele; ε4+ Risk, ε4+ Resilient, ε4- Risk and ε4- Resilient.
The ε4+ Risk group showed significantly faster decline in the global composite and the
composite of clinical progression when compared to all other groups. Further, the ε4+
Risk group showed significantly faster decline in the AIBL-PACC when compared to
the ε4- Risk and ε4- Resilient groups, however the difference between the ε4+ Resilient
group only trended towards significance. Finally, we report that the defined Cog-GRP
has no utility in defining cognitive decline in Aβlow CN older adults.

In Aβhigh CN older adults, where the Cog-GRP was able to differentiate rates of
cognitive decline, no significant differences in baseline cognition was apparent, whilst
Aβ burden was only observed to be different between the two “at risk” groups.
Suggesting that the observed cognitive outcomes were more dependent upon the Cog-
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GRP than driven by either of these factors. However, the lack of observable impact of
the Cog-GRP in in Aβlow CN older adults suggests that above threshold levels of brain
Aβ burden is required for observable cognitive decline. This has been reported
previously, where it is suggested that the absence of above threshold level of Aβ
burden, even in the presence of neurodegeneration, does not confer an increased risk
for cognitive decline [44]. Taken together these observations have potential
implication for the design of clinical trials. Specifically, trials would likely benefit
from the inclusion of both a measure of Aβ burden and risk stratification through, for
example, a genetic risk profile as presented in this study.

We have previously reported the ability of genetic factors to discriminate individuals
with accelerated rates of cognitive decline in the AIBL Study, above and beyond the
effects of APOE alone [8]. In the present study, the defined Cog-GRP polygenic
approach, showed that the ε4+ Risk group would reach clinically significant thresholds
of cognitive impairment in episodic memory (performance at 1.5 standard deviations
below controls, illustrated by the dashed line in Figure 4.2.1b) after 5 years, compared
to approximately 14 years in the ε4- Risk group and indeterminate years for the
remaining groups (due to positive slopes), including the ε4+ Resilient group. A slightly
shorter period of approximately 4 years was estimated for a clinically significant
decline in the global composite. The period of time to cross threshold in the ε4+ Risk
group is almost twice as fast as that when considering APOE alone (ε4+ Risk, 5 years;
ε4+ only, 9.6 years) whilst the ε4+ Resilient group shows no decline, suggesting that
the additional genes affected trajectories of cognitive decline above and beyond the
effects of APOE alone and are able to clearly define ε4 who decline or remain stable .
This is further emphasised by the negligible differences in cognitive performance at
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baseline in these groups. Finally, the defined ε4+ Risk group captures twice the number
of individuals (n=40) as APOE and BDNF alone (n=20). Taken together, these finding
suggest that broadening the scope in terms of genetic variants may provide more
clinical utility for implementation in clinical trials where cognitive decline is a primary
endpoint.

APOE, BDNF, KIBRA, KL, SPON1 and CSMD1 have all previously been associated
with both cross-sectional and longitudinal measures of cognitive change [7, 14, 17, 21],
whereby the independent influences of these genes have been investigated thoroughly.
In contrast, there is minimal research focused on the combined effects of these genes,
with the research that has been conducted focusing on combination effects with either
APOE or BDNF [8, 29]. In AD, polygenic investigations of disease progression and
cognition have focused broadly on those genes identified in case-control GWAS studies
[26-28]. While there have been a number of genetic risk scores that have been
developed and are associated with longitudinal and cross-sectional cognition, these
scores have had limited validation in at-risk preclinical AD cohorts. The decision tree
derived Cog-GRP reported in this study is novel in its use of cognitively associated
genes to predict decline in preclinical disease. Whilst the significant differences of large
effect observed at the 6th year of follow-up, which would likely be considered to be
clinically meaningful [45] (Cohen’s d > 1.0 across all cognitive composites), suggests
the strong potential for translation into clinical practice. Decision trees have been
widely investigated in neurodegenerative disease research, typically for diagnosis of
disease or disease stage. Investigators have used a range of approaches to achieve this:
neuropsychologically-framed interview questions to discriminate dementia, MCI and
controls [46], or between neurodegenerative disorders [46, 47], gene expression to
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diagnose AD [48], demographic variables to determine cognitive and functional change
[49], fMRI, behavioural and demographic information for diagnosis of AD [50],
MMSE, neurofibrillary tangles and gene expression to classify disease stages [51].
Similarly, the decision tree reported in this study was developed for possible clinical
use making the method’s ease of utility favourable.

The combination of genes associated with cognitive decline is a strength of this study
as it allows for the discrimination of rates of cognitive decline at preclinical disease
stages, however, the authors do acknowledge the limitations in the study. The decision
tree created within this study was statistically driven based on an episodic memory
composite derived from specific cognitive assessments, and the use of different
neuropsychological tests to create these composite scores could result in the creation of
a different genetic risk profile. Secondly, participants in the AIBL Study are not
randomly selected: they volunteer for involvement, likely accounting for a typically
slightly higher than average level of performance in cognitive assessments, which may
not represent the general population and might complicate replication in other cohorts.
In addition to these limitations, the small sample sizes of the groups after discrimination
by the Cog-GRP created could influence the results, and it will be important to replicate
these findings in other cohorts that are conducive to cross validation of comparable
cognitive endpoints.

Overall, this study reports a genetic risk profile, derived from a priori gene candidates
previously associated with cognitive performance, that can partition CN older adults
into groups that differ significantly in rates of cognitive decline. With the later disease
stage intervention strategy of previous AD clinical trials generally considered to have
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contributed to their lack of success and decline on clinical endpoints (cognitive tests)
still essential to assess efficacy, there is a now a focus on preclinical AD trials and the
appropriate means to select participants. The ease of clinical utility of the presented
Cog-GRP would not only readily allow its employment in clinical trial design for group
stratification but also for use in the retrospective analysis of prior clinical trial data.
Furthermore, Cog-GRP also supports the investigation of additional genes beyond
those associated with AD risk in GWAS, for defining polygenic risk scores for
cognitive decline in presymptomatic biomarker positive individuals.

4.2.6 Acknowledgements
Funding for the AIBL study was provided in part by the study partners [Commonwealth
Scientific Industrial and research Organization (CSIRO), Edith Cowan University
(ECU), Mental Health Research institute (MHRI), National Ageing Research Institute
(NARI), Austin Health, CogState Ltd.]. The AIBL study has also received support from
the National Health and Medical Research Council (NHMRC) and the Dementia
Collaborative Research Centres program (DCRC2), as well as funding from the Science
and Industry Endowment Fund (SIEF) and the Cooperative Research Centre (CRC) for
Mental Health – funded through the CRC Program (Grant ID:20100104), an Australian
Government Initiative. We thank all those who took part as subjects in the study for
their commitment and dedication to helping advance research into the early detection
and causation of AD. We kindly thank all AIBL Research Group members
(http://aibl.csiro.au/about/aibl-research-team/).

126

4.2.7 Competing Financial Interests
CLM is an advisor to Prana Biotechnology Ltd and a consultant to Eli Lilly. PM is a
full-time employee of Cogstate Ltd. DA has served on scientific advisory boards for
Novartis, Eli Lilly, Janssen, and Pfizer Inc. RNM is a consultant to Alzhyme. SML has
previously been a paid consultant to Alzhyme. CCR has served on scientific advisory
boards for Bayer Pharma, Elan Corporation, GE Healthcare and AstraZeneca; has
received speaker honoraria from Bayer Pharma and GE Healthcare; and has received
research support from Bayer Pharma, GE Healthcare, Piramal Lifesciences and Avid
Radiopharmaceuticals. VLV served as a consultant for Bayer Pharma; and received
research support from a NEDO grant from Japan. All other authors have nothing to
disclose.

4.2.8 Supplementary Data
4.2.8.1 Supplementary Materials and Methods
4.2.8.1.1 Study Participants
In addition to the 133 biomarker positive individuals, 406 CN biomarker negative older
adults enrolled in the AIBL Study, a prospective longitudinal study of ageing, were
investigated. Participants were classified as low (Αβlow; n=406) Aβ burden, based on a
tracer-specific SUVR threshold; <1.5, <1.10 and <0.62 for PiB, florbetapir and
flutemetamol, respectively, as previously described [39]. Nine individuals were
excluded from further analysis based on KL-VS homozygosity resulting in the inclusion
397 Αβlow CN adults.
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4.2.8.1.1 Statistical Analysis
All statistical analyses were performed using Rstudio (Rstudio Team 2015) Version
0.98.1103 for Macintosh [42]. Baseline demographic data analyses provided means,
standard deviations, and percentages across the cognitively normal sample. Differences
in rates of cognitive change between the groups defined by the Cog-GRP were assessed
in Αβlow group using random intercepts linear mixed-effects (LME) models and were
performed using the “nlme” package in R. A Cog-GRP group × Time interaction was
modelled across the entire sample, with the cognitive composites as the dependent
variables. All analyses for the AIBL-PACC co-varied for age.

4.2.8.2 Supplementary Results
4.2.8.2.1 Aβlow cognitively normal adults baseline demographics, genotype
frequencies and cognitive slopes
Table S4.2.3 shows the demographics, genotype frequencies and cognitive slopes of
the 406 Αβlow CN older adults included in the study. All composites presented with
positive rates of change in Aβlow CN adults, likely reflecting a practice effect in these
participants.

4.2.8.2.2 Performance of Cog-GRP groups on cognition in cognitively normal Aβlow
adults
No significant differences at baseline or between slopes in any composite measures
were observed when investigating cognitively normal Aβlow older adults (Table S4.2.4).
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Aβlow CN older adults
Age (years)

69.81 (6.20)

Female (%)

224 (56.42)
30 (7.56)

11 (8.66)

Years of
Education

150 (37.78)

51 (40.16)

(%)

72 (18.14)

31 (24.41)

145 (36.52)

34 (26.77)

Premorbid IQ (FSIQ)

107.80 (7.09)

Depressive Symptoms (GDS)

1 (1.21)

APOE (% ε4+ve)

79 (19.90)

BDNF (% Met+ve)

144 (36.27)

KIBRA (% T–ve)

172 (43.32)

KL (%VS–ve)

293 (73.80)

COMT (% Val+ve)

302 (76.07)

CSMD1 (% G–ve)

115 (28.97)

SPON1 (% A–ve)

358 (90.18)

Global Cognition*

0.0218

Clinical Progression*

0.0010

Verbal Episodic Memory*

0.0248

AIBL-PACC†

0.0213

Table S4.2.3 Baseline demographic information for Aβlow CN older adults
Baseline demographic, genotype frequencies and cognitive composites slopes for
cognitively normal (CN) older adults with low Aβ-amyloid (Aβlow) in the AIBL Study
(n=397). *Cognitive composites presented in SD/year, and the †Pre-Alzheimer’s
Cognitive Composite (AIBL-PACC) presented in 4×SD/year. AIBL-PACC controlled
for age. KL-VS homozygotes excluded (n=9). GDS, Geriatric Depression Scale; FSIQ,
WTAR-estimated FSIQ.
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ε4+ Risk
group

ε4+ Resilient
group

ε4– Risk
group

ε4– Resilient
group

β

β

β

β

Global

0.014

0.033

0.015

0.034

Clinical Progression

0.004

0.012

0.003

-0.008

Verbal Episodic Memory

0.026

0.028

0.017

0.038

AIBL-PACC

0.028

0.083

0.009

0.020

Table S4.2.4 Mean slopes for cognitive composites in Aβlow CN older adults
Mean slopes for cognitive composites (presented in SD/year) and AIBL-PACC
(presented in SD×4/year) in imaged cognitively normal (CN) older adults with low Aβ
(Aβlow n=397). *p<0.05 when comparing to the ε4+ at Risk group
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4.3 Epilogue
The study presented in this chapter aimed to investigate whether there is a synergistic
effect of genes previously associated with cognition, and further what the best
combination of these genes would be. To successfully achieve this aim, a decision tree
approach was implemented utilising genetic variants in seven genes, APOE, KIBRA,
KLOTHO, BDNF, COMT, SPON1 and CSMD1. The resultant episodic memoryderived cognitive gene risk profile included all variants apart from COMT and defined
four groups: APOE ε4+ Risk, ε4+ Resilient, ε4- Risk, ε4- Resilient. In measures of
verbal episodic memory, global cognition, and clinical progression the APOE ε4+ Risk
group declined significantly faster that all other groups. This defined cognitive gene
risk profile supports the notion that combining genetic variants associated with
cognition has utility for prediction of cognitive decline at the preclinical stages of AD,
even if independently they do not. It also provides further weight for such variants to
be considered for inclusion, along with AD risk associated variants, in polygenic risk
score PRS development.

With this view, and considering the lack of utility of AD risk weighted PRS and the
overriding impact that APOE ε4 has, the study presented in Chapter 5 attempts to
undertake a novel approach to combine both cognitive performance and AD risk
associated variants into a single PRS weighted by a phenotype more suited to the
desired outcome, being the prediction of cognitive decline in preclinical AD.
Employing such a phenotype specific approach to PRS weighting is hypothesised to
yield a PRS that would allow for a more accurate prediction of cognitive decline in
preclinical AD.
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Chapter 5
Please note that this online copy of the thesis does not contain the complete version of
Chapter 5

CHAPTER 5: Assessing the utility of a novel method
of weighting a priori candidate, cognition and ADrisk associated, genes for predicting cognitive decline
in preclinical AD.

5.1 Prologue
The preceding chapters in this thesis have explored several approaches for the
prediction of cognitive decline in the preclinical stages of Alzheimer’s disease (AD).
In Chapter 2 a polygenic risk score (PRS) weighted by AD risk was analyzed that as a
whole was significantly associated with cognitive decline. However, after the removal
of Apolipoprotein E (APOE) this association was lost, suggesting it had negligible
utility above and beyond APOE. The following chapters aimed to broaden the scope
for selection of genetic variants to be included in polygenic approaches to predict
longitudinal cognitive performance. The studies presented in Chapter 3 provided
evidence that a targeted selection of genes with a priori evidence of association with
cognitive performance had utility. Whilst Chapter 4 suggested that a genetic risk profile
combining the effects of the cognitive risk genes examined in Chapter 3 could be used
to define a population of individuals declining at significantly accelerated rates.
Chapters 3 and 4 thus suggest that broadening the scope of genetic variants included in
a PRS may provide increased utility. However, as suggested by the study presented in
Chapter 2, the choice of weighting to apply to such a PRS needs to be carefully
considered.
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These preceding chapters have therefore laid the foundation and provided the
supporting evidence for the study presented in this chapter, which hypothesizes that
through the use of an endophenotype weighting of genetic variants previously
associated with AD risk and cognitive decline, improved prediction of preclinical rates
of cognitive decline would be possible. To address this hypothesis, this study will
address the fourth and final aim of the thesis, being to determine a method of weighting
genes associated with both AD-risk and cognition, for use in a genetic risk score to
improve the prediction of preclinical cognitive rates of change.

To achieve this aim, it was proposed to combine genes and variants studied in this
thesis, that have previously been associated with either an increased risk for AD
(Chapter 2) or associated with cognitive performance (Chapter 3 and 4). These variants
would be weighted by effect sizes for decline in verbal episodic memory, one of the
earliest cognitive domains to decline, [1-3], in a reference sample of cognitively normal
individuals with high brain Aβ-burden. The resultant effect sizes allowed for the
calculation of a cognitively weighted PRS (cwPRS), the performance of which was then
assessed in a further test sample with respect to decline in performance across multiple
cognitive composites.

Prologue References:
1. Elias, M.F., et al., The preclinical phase of Alzheimer disease: a 22-year prospective study
of the Framingham Cohort. Archives of neurology, 2000. 57(6): p. 808-813.
2. Grober, E., et al., Memory impairment, executive dysfunction, and intellectual decline in
preclinical Alzheimer's disease. Journal of the International Neuropsychological Society,
2008. 14(2): p. 266.

142

3. Derby, C.A., et al., Screening for predementia AD Time-dependent operating
characteristics of episodic memory tests. Neurology, 2013. 80(14): p. 1307-1314.
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CHAPTER 6: Overall Discussion

The limited success of clinical trials for effective disease modifying treatments for
Alzheimer’s disease (AD) has, in part, been attributed to targeting the disease at
symptomatic clinical stages where underlying neurodegeneration is well established
[1]. In recognition of this there has been an increased research focus on characterising
the preclinical disease stages of AD thereby enabling the implementation of disease
modifying interventions at stages where the disease is pre-symptomatic [2]. To achieve
this requires the accurate identification of pre-symptomatic individuals who will
progress to develop AD (i.e. preclinical AD) and subsequently those who are most
likely to present with the fastest rates of change in clinical end-points. Together, the
identification of these individuals is critical for the design of preventative or early
intervention clinical trials.

The accuracy of identification of individuals at the preclinical stages of AD has
improved greatly through the advances in brain imaging, i.e. Ab-amyloid (Ab). This
is reflected in both the current diagnostic criteria, which incorporates high brain Ab
burden [2], and the use of Ab imaging in pre-trial screening of participants. The major
limitation of imaging techniques is the high cost involved in serial imaging, deceasing
its feasibility as a primary outcome measure in large clinical trials. At present, the
efficacy of clinical trials is predominantly determined through the use of a primary endpoint of arresting decline in cognitive performance. This places importance on the
ability to identify those individuals whose cognition declines at an observable rate
within the trial time frames (typically up to 2 and 4 years for Phase 2 and 3, respectively
[3]). A major difficulty with this approach is the variability known to exist in rates of
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cognitive performance at these earliest stages of the disease process between
individuals [4].

As outlined in detail in Chapter 1, while the imaging of Ab has increased the accuracy
of preclinical AD identification, and thus identifying those who will eventually exhibit
cognitive decline, it is less sensitive at predicting the rate of this decline. This suggests
that, while Aβ is a necessary condition for AD, other factors (e.g. imaging, fluid
biomarkers or genetics) influence the relationship between this biomarker and clinical
disease progression. Recently, there has been an increased focus on tau imaging, the
results showing it is associated with cognitive performance [5]. Cerebrospinal Fluid
(CSF) biomarkers have been shown to predict risk of AD and cognitive performance.
The collection of CSF biomarkers is invasive and so, as with imaging, does not present
a viable option for serial collections. At present, there is limited information regarding
the genetic factors defining the rates of cognitive performance in the preclinical stages
of AD. However, if genetic factors could be established, a combinatory approach with
genetics augmenting preclinical AD identification (through Ab imaging), could present
a practical method to predict the rates of cognitive decline at the early stages of the
disease.

Cognitive performance has been observed to be heritable and highly polygenic [6]. In
addition to genetic variants identified as conferring risk for AD (as reviewed in [7]), a
number of single nucleotide polymorphisms (SNPs) have been associated with
cognitive performance independent of an association with AD risk [8-16]. Several
methods are currently used for the investigation of combined genetic effects on disease
risk and phenotypes [17]. In AD, polygenic influences have been reported for disease
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risk [18, 19], pathological biomarkers [19-22], and cognitive performance [23].
However, studies reporting on polygenic effects in cognitively normal elderly,
particularly on cognitive performance, have had varying outcomes [23-32]. The
discrepancy in outcomes could be partly due to a lack of knowledge regarding
participants’ Aβ status and thus whether they are truly representative of the preclinical
stages of AD. This thesis aimed to provide clarity concerning the inconsistent results
previously reported, and further, to improve the methods by which combinations of
genetic variants are investigated, particularly with respect to preclinical cognitive
performance in AD. The overarching hypothesis of this thesis was that a combination
of genetic factors will influence cognitive rates of change in preclinical Alzheimer’s
disease.

To clearly define factors, genetic or otherwise, that contribute to changes in cognition
at the earliest pre-clinical stages of AD, highly characterised longitudinal cohorts are
required. This thesis benefits from access to a world leading longitudinal cohort, the
Australian Imaging, Biomarkers and Lifestyle Study of Aging (AIBL). The AIBL study
has collected extensive data from participants at 18-monthly intervals including
cognitive, neuroimaging and biological assessments. Currently, the study consists of
7.5 years of longitudinal follow-up, allowing for a detailed analysis of preclinical
performance.

Initially, I implemented established strategies to assess combined genetic influence of
established AD risk genetic variants on preclinical cognitive performance (Chapter 2).
AD-risk effect-size weightings, derived from large AD-risk GWAS [33], were applied
and resultant PRSs assessed with respect to cognitive performance. In order to address
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the potential biased selection of genetic variants and thus encompass a wider range of
gene variants, I then investigated genetic variants previously associated with cognitive
performance and assessed their influence in preclinical AD, both independently
(Chapter 3) and in combination (Chapter 4). Finally, a novel method of phenotype
derived effect-size weighting was applied to both AD-risk and cognition associated
gene variants, which allowed for them to be appropriately combined into a PRS and
used to predict preclinical cognitive performance (Chapter 5).

Polygenic risk scores weighted by a measure of AD-risk have limited utility for the
prediction of preclinical cognitive performance.
The most common approach currently utilised for investigating the influence of genetic
variant combinations in AD, is through the calculation of AD-risk weighted Polygenic
Risk Scores (PRSs). Using the calculation methods previously described [19], I
assessed the impact of genetic variants previously associated with AD risk on measures
of cognition at a preclinical stage (Chapter 2). In addition to this aim, associations
between an AD-risk weighted PRS, and AD fluid and imaging biomarkers were also
investigated. Further, the PRS was investigated both with (PRSc̄APOE) and without
(PRSs̄APOE) Apolipoprotein E (APOE), to understand the dependence of these
associations on carriage of the APOE e4 allele. The results presented in this chapter
confirmed previous reports of significant associations between PRSc̄APOE and
pathological biomarkers, particularly increased neocortical Ab [30], and reduced levels
of CSF Ab [19, 21, 28] and Ab:total-tau ratios. The PRS s̄APOE was significantly
associated with increased levels of CSF total-tau [27] and phospho-tau [27]. It could be
speculated that the contrasting results when including or excluding APOE could be
explained by differences in genetic associations with specifically different aspects of
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AD pathology. It is currently well accepted that APOE is strongly associated with brain
Ab burden [34], and it can be hypothesised that the additional genes included in the
PRS calculation are more closely associated with Tau. Several studies have observed
an influence of a number of these genes on in vivo pathological changes in Tau and its
propagation [35-37].

As previously established, the use of brain imaging data available within the AIBL
study allows for the true identification of individuals in the preclinical stages of AD.
When specifically investigating the association between PRSs and cognitive
performance in a preclinical AD sample (defined as cognitively normal older adults
with high neocortical Ab) the following findings were reported. Significant
associations were reported between PRSc̄APOE and composite measures of cognition,
specifically global cognition, verbal episodic memory, and the AIBL Pre Alzheimer’s
Cognitive Composite (AIBL-PACC). These associations were observed at both study
baseline and in terms of longitudinal change. However, after the removal of APOE from
the calculation of the PRSs̄APOE no significant associations were recorded.

These results confirm previous findings reported in the literature, particularly the loss
of association after removal of APOE [24, 25]. Additional investigations found that
individuals within the upper quartile of PRSc̄APOE scores declined cognitively at rates
significantly faster than individuals within all other quartiles. However, closer
examination of the distribution of APOE e4 carriage amongst these quartiles revealed
that this association is most likely driven by the influence of this distribution. It was
observed that the upper quartile included all of the APOE e4 homozygote individuals
and a significant proportion of APOE e4 heterozygotes. Further, the proportion of
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APOE e4 heterozygotes within quartiles declined with reducing risk. The chapter
described above represents one of a small number of studies investigating the utility of
AD-risk weighted PRSs for the prediction of preclinical cognitive performance in AD.
To the best of the author’s knowledge it is the first to thoroughly investigate the
influence of APOE within a PRS. Specifically, the saturating effect of APOE, and the
spread of e4 alleles over the range of the PRS, particularly influencing investigations
concerning cognitive measures.

Results from this study suggest that while PRSs calculated in this manner can be utilised
for the prediction of AD and pathological AD biomarkers, they lack utility when
predicting rates of preclinical cognitive decline. Particularly, this is supported by the
observed APOE dependent cognitive association. These results, combined with the
hypothesis that the genetic architecture of AD-risk likely differs from that of AD
progression, informed the decision to investigate genes with a priori evidence of
influence over broad cognitive performance (Chapter 3).

Genetic variants previously associated with broad cognitive performance influence
rates of cognitive decline in a preclinical AD sample.
A perceived weakness of previous efforts that have investigated polygenic risk in AD
is the biased selection of genetic variants which have focused largely on those
associated with AD diagnosis. A number of genes and gene variants have been
associated with cognitive performance and have been speculated to influence decline
in preclinical AD. However, due to a lack of association with clinical AD diagnosis
have been largely overlooked or excluded [24] from previous polygenic approaches.
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One such example is the non-synonymous variant (rs6265; Val66Met) within brain
derived neurotropic factor (BDNF). Our group has extensively reported its influence on
rates of cognitive performance [9, 10], yet it has negligible influence on AD risk [38].
In previous studies in AIBL, the effect of BDNF Val66Met on longitudinal cognitive
performance is seen above that of APOE e4 in preclinical AD, specifically in
cognitively normal older adults having increased neocortical Ab burden [9, 10]. In
addition to BDNF, a number of other genetic variants have been associated with
cognitive performance that are independent of AD risk. For these reasons, it was the
aim of Chapter 3 to assess the effects of genes with a priori evidence for association
with cognition on cognitive rates of change in preclinical AD.

Previous studies have shown associations between the gene variants investigated in
Chapter 3 (Kidney Brain expressed protein, KIBRA [39]; F-Spondin, SPON1 [16];
Catechol-O-methyltransferase, COMT [40]; Klotho, KL [41]) and cognitive
performance. No such associations were observed here when assessing the independent
influence of each variant in the current studies. However, in the presence of an elevated
brain Ab burden and APOE e4 carriage a number of significant associations are found.
It should be noted that the studies presented in this thesis are the first to investigating
the interactional effects of the gene variants of interest with Ab burden and APOE e4
carriage.

Investigation of KIBRA rs17070145, in combination with Ab burden and APOE e4
carriage, showed an influence of the gene over memory performance and hippocampal
atrophy[14]. Specifically, individuals who had high Ab burden, carried an APOE e4
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allele, and homozygote for the KIBRA C allele declined significantly faster than those
carrying at least one copy of the KIBRA T allele [14].

The findings reported in Chapter 3 support those from previous studies reporting a
protective influence of the KIBRA T allele over cognitive performance [13, 39, 42-45].
Gene expression [39, 46-48], brain activity [13, 39], and functional studies [46, 49, 50]
investigating KIBRA support the hypothesis that the KIBRA T allele promotes resilience
to cognitive decline. KIBRA expression occurs mainly in those areas responsible for
memory function [39, 46], with those carrying a T allele reporting increased
hippocampal activity during memory tasks [13, 39]. More recently, the postsynaptic
KIBRA protein has been reported to mediate tau associated memory decline [50].

Assessment of SPON1 rs11023139 resulted in trends towards significance when
investigating the independent effect of this variant on cognitive performance,
particularly in measures of global cognition and verbal episodic memory. As in the
analysis of KIBRA, after interaction with Ab burden and APOE e4 carriage, significant
associations between SPON1 rs11023139 and cognitive performance were observed.
High Ab burden, carriage of an APOE e4 allele, and a SPON1 A allele resulted in
cognitive decline at a significantly faster rate compared to those with the same Ab
burden and APOE e4 carriage carrying no SPON1 A alleles. These findings related to
this variant are the first to build upon those initially reported in the Alzheimer’s disease
neuroimaging initiative (ADNI) [16].

Biologically, functions of the protein (Spondin-1) encoded by SPON1 support the
genetic variant findings described above. Specifically, Spondin-1 is involved in
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neuronal development in embryos [51], regeneration of axons [52], and regulation of
amyloid precursor protein (APP) cleavage by beta-secretase [53]. The specific effects
of identified genetic variation within SPON1 have not been assessed, and further such
investigation will be valuable.

In contrast with the analysis of the two previous gene variants, analysis of COMT
Val158Met and KL-VS variations revealed no significant associations with cognitive
performance were observed, even after interaction with Ab burden and APOE e4
carriage. While the current study assessing COMT Val158Met was unable to replicate
previous reported associations with cognitive performance [54-58], it is not the first to
report no effect of the variant [59-61]. Likewise, previous reports investigating the
influence of KL-VS have differed with a number reporting that heterozygosity was
associated with improved cognitive performance or reduced decline [12, 41, 62, 63],
and a further study similarly reporting no associations [62].

While significant associations were not observed for all variants investigated here, it
cannot be assumed that they confer no influence over preclinical cognitive decline. As
observed in KIBRA and SPON1, where significant associations were only observed
after interaction with APOE, it could be hypothesised that variants within KL and
COMT require combination with additional genetic factors before their impact is
observable. As such, studies outlined in Chapters 4 and 5 were undertaken that aimed
to determine the influence on cognitive performance of the combination of the
cognition associated genes studied in Chapter 3 (Chapter 4) and then the combination
of both AD-risk and cognition associated genes (Chapter 5).

156

Combining genes previously associated with cognition can define profiles of risk for,
and resilience to, preclinical decline in cognition.
The Initial aim was to focus on those genes previously associated with cognitive
performance, specifically, investigate whether there is a synergistic effect of genes
previously associated with cognition, and further what the best combination of these
genes would be (Chapter 4). Investigating a reduced number of genes known to
influence cognition was proposed to be optimal for use in a simple method for routine
clinical use.

Clinically, decision tree based risk profiles have been utilised for risk triage and disease
differentiation in neurodegenerative disorders [64-68]. Thus, a cognitive genetic risk
profile (Cog-GRP) was developed using a statistically calculated decision tree driven
by longitudinal change in verbal episodic memory. This profile was developed in
cognitively normal individuals with high neocortical Aβ burden. In addition to the
genes investigated in the previous chapter (KIBRA, SPON1, COMT, KL), APOE [8],
BDNF [9, 10] and CSMDI (CUB and Sushi Multiple Domains 1) [15, 69] were also
included in the definition of the Cog-GRP based on their associations with cognitive
performance in other studies.

Calculation of the Cog-GRP resulted in the utilisation of all genes with the exception
of COMT. No significant associations were observed independently between COMT
and cognition, as presented in Chapter 3. This finding supports the results of a number
of previous studies including a large meta-analysis [70]. Four classifications were
determined based on the Cog-GRP after the groups were collapsed based on sample
size and similarities in rates of cognitive change; ε4+ Risk, ε4+ Resilient, ε4- Risk and
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ε4- Resilient. The most at risk group, ε4+ Risk, was reported to decline significantly
faster on additional measures of cognition including; global cognition and clinical
progression, compared to all other groups. Further, it was observed that when
comparing to APOE alone, those individuals in the ε4+ Risk group, declined to a
clinically significant threshold (1.5 standard deviations lower in cognitive performance
than controls) twice as fast, 5 years compared to 9.6 years. While the decision tree
method is not novel, the combination of the genes presented here in the Cog-GRP is
the first to the author’s knowledge to be published.

A phenotypically relevant weighting of genetic variants can define a polygenic risk
score for preclinical cognitive performance in the presence and absence of APOE.
The PRSc̄APOE and PRS s̄APOE described in Chapter 2 were calculated through applying
an AD-risk weighting. The admixture of additional genetic variants was observed to
have no effect above that of APOE alone, despite these genes having been previously
associated with AD-risk and cognitive performance [24, 71-76]. In additional, despite
being previously associated with cognition, the genes presented in Chapters 3 and 4
have been, at best, weakly associated with AD risk. For these reasons, when combining
AD-risk and cognitive-risk genes the current most utilised method of polygenic risk
score calculation, AD-risk weighting, was deemed inappropriate. As such, it was aimed
to determine a method of weighting genes associated with both AD-risk and cognition,
for use in a genetic risk score to improve the prediction of preclinical cognitive rates
of change (Chapter 5).

While previously published PRSs, with conservative SNP inclusions, have largely not
included variants associated with cognitive performance, or have excluded them based
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on lack of influence [24], results from the aforementioned Cog-GRP provides evidence
for their inclusion. To accurately account for the impact of the included genetic variants
on preclinical cognitive performance, each was weighted by an effect size associated
with verbal episodic memory performance over 7.5 years. As in the development and
testing of previous genetic associations, these weightings were created and tested in a
preclinical AD sample as defined by cognitive normality and high Ab burden. The
resulting PRS (cwPRS) was tested in an additional sample and found to be associated
with cognitive performance, specifically, verbal episodic memory, global cognition and
the AIBL-PACC. The cwPRS was also associated with cognitive performance after the
exclusion of APOE from score calculation. This thesis therefore presents, to the best of
this researcher’s knowledge, the first cognitively weighted PRS developed in
preclinical AD. It is also one of a small number of PRSs with the ability to predict
longitudinal cognitive performance in a cognitively normal sample.

6.1 Limitations
Despite attempts to overcome weaknesses within the studies presented, the following
limitations of the results reported in this thesis are acknowledged. Limitations exist
which are specifically related to the cohort utilised in the studies. The Australian
Imaging, Biomarkers and Lifestyle Study of Aging (AIBL) cohort, data from which
was utilised in all studies presented here, represents a Caucasian population which is
not representative of the wider community in Australia or globally. The voluntary
recruitment of AIBL participants has led to high levels of education observed in the
cohort which results in cognitive performances above expectations [77]. As of 2018 the
AIBL Study has an extensive 7.5-year follow-up period. Whilst this is valuable when
investigating the AIBL study independently, it has the potential to hinder the ability to
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validate these results in similar studies with reduced follow-up periods. Despite AIBL
being a relatively large longitudinal cohort, at times reduced sample sizes are reported
due to genetic stratification. Some studies presented in this thesis and therefore the
reference profiles and measures developed may be difficult to replicate when
investigated in smaller or less comprehensive cohorts.

This thesis focused on rates of cognitive performance in preclinical AD. It aimed to
measure performance in cognitive domains known to be impacted in the early stages of
AD (particularly verbal episodic memory). For this reason, statistically derived
cognitive composites previously developed in the AIBL study were utilised. This is
considered a limitation as the cognitive composite scores were developed based on the
AIBL neuropsychological test battery, which differs from batteries administered in
other studies. The absence of similar scores for the precise measurement of cognitive
performance could impact on the ability to validate the results in other cohorts. At the
time of completing this thesis there was a concerted effort underway amongst the
cognitive arms of large prospective longitudinal cohorts to address this and define
cognitive measures which would allow for future ease of cross-validation.

Finally, it is widely accepted that the APOE e4 allele is the strongest genetic risk factor
for AD, with carriage of one increasing an individual’s risk for AD by four times and
carriage of two by twenty times [78]. Within the studies presented here, and in the wider
community, there is an overlap observed between increased neocortical Ab-amyloid
burden and carriage of an APOE e4 allele. This could confound the investigations of
genetic interactions in those with high Ab burden. That being said, in Chapter 5, this
thesis presents a novel PRS that shows utility independent of APOE. There was an
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observable reduction in association with the exclusion of APOE and so further studies
are recommended to address this potential confounder.

6.2 Future Directions
Published studies investigating polygenic risk in AD currently focus on AD-risk as a
weighting measure [18-28, 31, 32, 79-87]. Only recently have studies been presented
taking into account addition phenotypic weighting factors [88]. Further, even in these
recent studies, a lack of understanding of polygenic risk in the prediction of preclinical
cognitive performance in AD remains.

The research presented here confirms the APOE dependent nature of associations
between AD-risk weighted PRSs and cognition [24, 25], and further describes the
influence of specific genetic variants on cognitive performance in preclinical AD. To
build upon these findings, a phenotype weighted PRS was developed and found to be
associated with cognitive decline over 7.5 years. Further validation of the methods
investigated in this thesis is required in other independent longitudinal studies with
similar phenotypic information. This will increase the ability to assess clinical utility of
the work presented. Outlined here are future directions of the work currently presented,
including those which would possibly allow for its transition into a clinical setting.

Presented in all studies in the current thesis are results based on the assessment of
previously developed cognitive composite scores [89]. These scores were statistically
driven to best represent the verbal episodic memory domain, global cognition, and
changes that occur in preclinical AD (AIBL-PACC) [90]. As described in the
limitations above, while these composite scores strengthen the study by specifically
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measuring domains impacted early in AD, there is a lack of comparable scores in the
other large cohort studies. A number of these studies exist, most namely ADNI,
however differences in the cognitive battery undertaken present difficulties for
replication. In order to replicate the results presented in this thesis, the development of
comparable cognitive composite scores in additional large cohort studies would be
required, followed by development of reference measures for the weighting of genetic
variants. Presented here are studies reporting on weighting of genetic variants in
relatively small sample sizes (~150-600 participants). Currently the most utilised
reference measure for the weighting of PRSs, is the odds ratio for AD-risk as calculated
in a meta-analysis from the International Genomics of Alzheimer’s Project (IGAP)
consisting of >50,000 participants [33]. For wide scale utility of the methods discussed
in this thesis, larger reference cohorts would be required to ensure wider validations.

Once the results presented in the current study are adequately validated, the aim would
be for the methods and scores described to transition from research use into a clinical
setting, with particular utility in patient selection for clinical trials. Clinical trials
utilising genetics are currently occurring in a number of diseases including in AD. The
TOMORROW Study aimed to focus drug treatment on individuals based on their
APOE genotype and Translocase of Outer Mitochondrial Membrane 40 (TOMM40)
repeat status, although it has recently failed due to lack of treatment effect.

As discussed previously, neocortical amyloid imaging alone is unable to predict
individuals decline. The polygenic approaches developed here are targeted at
individuals with high Ab which needs to be identified through amyloid imaging. The
recent development of plasma Ab biomarkers being reported to predict brain Ab
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burden, could mean this can be utilised in the identification of individuals at risk of
decline [91]. The combination of plasma biomarkers and genetic testing would
represent an inexpensive and relatively non-invasive screening method for clinical
trials, as a single blood sample would be sufficient for both tests.

Multimodal approaches for the development of risk profiles in preclinical AD are
valuable. In addition to genetic variation, amyloid imaging and CSF biomarkers, recent
developments in the mapping of brain iron have been shown to predict cognitive
performance [92]. The use of multiple methods to predict cognitive performance will
increase the likelihood of selecting appropriate clinical trial participants. Genetic
testing would not only allow for the selection of appropriate trial cohorts after the
identification of those with high brain Ab burden, but could also reduce the number of
individuals initially requiring amyloid imaging for confirmation of their preclinical AD
status.

Due to the biological actions of drug candidates for AD treatments, many of these result
in adverse side effects [93]. The polygenic approaches described here could assist in
the movement towards personalised medicine [94], wherein individuals are prescribed
medications, including adjusted doses, dependent on their expected rate of preclinical
decline. Individuals expected to progress towards disease at an increased rate could
require more aggressive levels of treatment to halt decline. Conversely, tailoring
treatments based on rates of preclinical decline could also reduce side effects in those
patients not declining at accelerated rates, by possibly lowering required dosages.
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Finally, while outcomes from the current study aim to play a role in the enrolment of
appropriate individuals for clinical trials going forward, they could also have utility in
the analysis of historical clinical trial data. Particularly in AD, there is a wealth of
information from clinical trials which is being further investigated to better understand
the reasons for their failures [95]. Improving the understanding of previous clinical
trials and the reasons for their failures is important in moving forward with new
treatments and targets. Retrospective trial analyses and a more complete understanding
of the natural history of AD have resulted in the current changes to focus clinical trials
on the preclinical disease phase. Having a better understanding of individuals’ genetic
composition could also assist in understanding the possible reasons for the prior trial
failures. This could include determining whether, based on the time frames and
individuals investigated, any change in cognitive performance could have been
expected.

6.3 General Conclusion
This thesis provided a thorough investigation of genetic influence over rates of
cognitive performance in preclinical AD. The work highlights the importance of
polygenic approaches in association studies and the limitations of the current methods,
particularly in preclinical disease. The findings provide evidence that cognitive
performance in preclinical AD is genetically influenced and that the genetic
architecture of cognitive decline does not mirror that of AD-risk. This understanding of
the genetic influences over rates of preclinical cognitive performance has significant
implications in clinical trial design. Combined genetic approaches may assist the
selection of those individuals that are likely to show rapid cognitive decline for
inclusion in preclinical AD trials, allowing these trials to be conducted in feasible time
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frames. Whilst further study is required to validate and build on the results presented
here for their transition into a clinical setting, appropriate participant inclusion in AD
preclinical trials would improve the likelihood of identifying an appropriate treatment
for AD, reducing the enormous global impact of the disease.
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